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1 INTRODUCTION 
1.1 Skin structure and immune sentinels 
The skin is the body’s largest organ and the one with the biggest interface with the 
environment. It provides protection against physical and chemical injuries and acts as 
the first-line defence against microbial pathogens. Immune surveillance in such an organ 
is very complex, it requires a network of structural as well as immunological cells and 
pathways working together in perfect harmony.  
The skin can be divided into two different compartments, the epidermis and the dermis 
with different structural and immune cells present in each compartment (Fig. 1). 
Epidermis 
The epidermis is the outer layer responsible for the vital functions of the skin. It consists 
of four layers: In the innermost layer, the stratum basale, epidermal keratinocytes are 
continuously generated. As they migrate towards the surface of the epidermis, these 
cells form the stratum spinosum while undergoing terminal differentiation with cell cycle 
arrest, loss of adherence to the basement membrane and increase in keratin production. 
The stratum spinosum is followed by the stratum granulosum, with tight junctions and 
lamellar granules containing extracellular structural proteins, and various antibacterial 
peptides such as cathelicidin and β-defensin 2 (Oren et al. 2003, Braff et al. 2005). The 
final and outer layer is the stratum corneum consisting of keratin-rich corneocytes, which 
among other functions prevent epidermal water loss making them an essential part of 
the skin barrier. 
Immune cells residing in the epidermis consist mostly of Langerhans cells (LCs) while T 
cells are rare and limited to very few CD8+ T cells that can be found in the stratum 
spinosum and stratum basale (Nestle et al. 2009).  
Keratinocytes 
Keratinocytes (KCs) are first in line to encounter foreign and possibly dangerous agents 
and they play an essential role in promoting skin immune responses. Their 
inflammasome machinery and ability to express toll-like receptors (TLRs) - including 
TLR1, TLR2, TLR3, TLR4, TLR5, TLR6 and TLR9 enables keratinocytes to recognize 
pathogen-associated molecular patterns (PAMPs) of microbial origins (Lebre et al. 
2006). Keratinocytes also express NOD-like receptors (NLRs) that can recognize danger 
associated molecular patterns (DAMPs) including toxins and irritants (Nestle et al. 2009). 
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During skin infections, keratinocytes produce antimicrobial peptides (AMPs) among 
which are β-defensin and cathelicidins as well as pro-inflammatory cytokines including 
IL-1β, IL6, IL18, and TNFα (Albanesi C1 2005). Activated keratinocytes attract effector 
T cells to the skin through the expression of CC-chemokines ligand 20 (CCL20), CXC-
chemokine ligand 9 (CXCL9), CXCL10 and CXCL11 (Albanesi C1 2005).  
Keratinocytes have also been described to induce functional responses in memory T 
cells. They can process peptide antigens or exogenous peptides, present it to CD4+ or 
CD8+ T cells which in turn induce both Th1 and Th2-type cytokine production as well as 
target cell lysis, respectively (Black et al. 2007).  
Langerhans cells  
Langerhans cells (LCs) represent a specialized subset of dendritic cells (DCs) that are 
found in the epidermis. They survey the epidermis for antigens using their extended 
dendrites and migrate to the lymph nodes upon antigen-mediated activation. Migratory 
LCs express less E-cadherin, a homotypic adhesion molecule that anchors LCs to 
neighbouring keratinocytes. On the other hand, they show increased expression of MHC 
molecules, co-stimulatory molecules such as CD40 as well as CC-chemokine receptor 
7 (CCR7), which is essential for LC migration to the skin-draining lymph nodes (Merad 
et al. 2008). Recently, more attention is being given to the role of LCs in the induction of 
tolerance to peripheral antigens in the steady state (Steinman et al. 2003, Shklovskaya 
et al. 2011, van der Aar et al. 2013).  
 
Dermis 
The dermis is anatomically more complicated than the epidermis and is the residence 
for most skin immune cells. It consists of an extracellular matrix formed by fibroblasts 
that produce collagen, elastin and structural proteoglycans. It also contains a pool of 
different immune cells including mast cells, macrophages, DCs, T cells and a population 
of innate lymphoid cells (ILCs) (Emilsson, Breaker 2002). 
Dendritic cells  
The dermis-resident DCs play a critical role in cell-mediated immunity. DCs engulf 
antigens, become activated by innate immune mechanisms and exposure to pro-
inflammatory cytokines, and undergo maturation as they migrate to draining lymph 
nodes. Mature DCs have an enhanced capacity of antigen presentation with increased 
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expression of surface MHC molecules and co-stimulatory molecules like CD80 and 
CD86 (Pierre et al. 1997), (Schuller et al. 2001). In the lymph nodes, mature DCs come 
in contact with naïve T cells for antigen presentation resulting in T cell-proliferation, clonal 
expansion and differentiation into memory/ effector T cells. The generated T cells are 
antigen-specific, express skin homing receptors and can be rapidly recruited to the site 
of initial antigen encounter in the skin. 
T cells  
T cells are strongly present in the skin at numbers two times higher when compared to 
the blood. In the dermis, T cells, mostly memory CD4+ or CD8+ T cells that express the 
cutaneous lymphocyte-associated antigen (CLA), preferentially cluster around post 
capillary venules. Their role in the first-line defence against secondary antigen challenge 
makes them important effector cells of skin immunity (Romani et al. 2012).  
Conventional T cells are the main players in various inflammatory skin diseases. T helper 
1 (Th1) cells are present and active during skin infection with intracellular organism and 
in autoimmune diseases such as psoriasis while Th2-cell responses are associated with 
allergic skin diseases like atopic dermatitis. The role of other T helper cell subtypes such 
as Th17 cells and Th22 cells in the pathology of different inflammatory skin diseases has 
also been the focus of several studies (Weaver et al. 2007, Nograles et al. 2009). 
Unconventional T cells including γδ T cells, natural killer T cells (NKT) and invariant NKT 
(iNKT) cells are also found in the skin and are associated with inflammatory diseases 
and skin carcinogenesis (Nestle et al. 2009). 
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Figure 1. Skin anatomy and cellular effectors (Nestle et al. 2009). 
The different layers of the skin give it its functions from providing a physical barrier to maintaining 
the body temperature and gathering sensory information from the surrounding environment. The 
cells residing the skin provide the skin with its role in the immune system. The epidermis contains 
several layers and is responsible for the barrier function of the skin. Immune cells in the epidermis 
include Langerhans cells and very few CD8+ cytotoxic T cells. The dermis contains many 
specialized cells including different subtypes of dendritic cells (DCs), T helper cells, macrophages, 
mast cells and fibroblasts.  
 
1.2  Inflammatory skin diseases 
1.2.1 Allergic contact dermatitis  
Allergic contact dermatitis (ACD) is a common acute inflammatory skin disease usually 
caused by contact with chemicals. In Europe about 20% of the general population suffer 
from contact allergy to at least one allergen (Peiser et al. 2012). Contact allergens are 
small organic molecules with chemical activity and a molecular weight of ≤ 500 Dalton 
called “haptens”. They include metal ions and salts such as nickel, chromate fragrances 
and dyes and are found in a lot of cosmetics, jewellery and at different work places which 
explains the classification of ACD as a major cause of occupational skin diseases. The 
risk of developing ACD depends to a large extent on the exposure patterns and habits. 
For instance, the higher prevalence of ACD in women than in men (Thyssen et al. 2007) 
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can be attributed to the habit of wearing nickel-containing jewelry rather than genetic 
factors. However, genetic predisposition cannot be ruled out in ACD, since among the 
high rate of exposure only a minority actually develops the disease.  
Because of their low molecular weight, haptens can pass the stratum corneum and move 
further to the basal layer without being recognized by the immune system until they 
covalently attach to self-proteins and become immunogenic. When bound to cytoplasmic 
proteins, they are presented to CD8+ T cells on MHC class I molecules, whereas binding 
to extracellular tissue proteins leads to their capture and process by antigen presenting 
cells (APCs), which present them on MHC class II inducing a CD4+ T cell response 
(Martins 2011).  
 
Pathophysiology 
ACD is identified as a T cell- mediated response to contact allergens (Kimber, Dearman 
2002) that occurs in two phases, a sensitization phase and an elicitation phase.  
During the sensitization phase, the irritant effect of haptens generates danger signals in 
the skin inducing innate immune responses through the activation of TLR2/TLR4 (Martin 
et al. 2011) and the inflammasome (Watanabe et al. 2007). This results in the production 
of pro-inflammatory cytokines including IL-1β, TNF-α and GM-CSF which support the 
activation of DCs upon antigen uptake. Activated DCs produce more IL-1β, change their 
profile of chemokines receptors and migrate to the regional lymphnodes. There, they 
present the antigen to naïve T lymphocytes and drive their differentiation into effector T 
cells. These hapten-specific T cells then enter the blood circulation and are preferentially 
directed to the skin due to their expression of the cutaneous lymphocyte antigen (CLA).  
In the elicitation phase and within a couple of hours following a secondary exposure to 
the same hapten, a variety of immune cells including mast cells, neutrophils as well as 
hapten-specific and non-specific T cells infiltrate into the challenged skin. Both CD8+ and 
CD4+ T cells are recruited to the site of inflammation and peak within 24-48 h after 
challenge. Whether the recruited CD4+ T cells are Th1 or Th2 is highly dependent on the 
nature of the hapten. Studies in animal models showed infiltration of CD4+ T cells 
expressing Th1-specific chemokine receptors upon sensitization and challenge with the 
hapten dinitrofluorobenzene (DNFB) while a greater influx of T cells expressing 
chemokine receptors consistent with Th2 cells was observed when using the hapten 
oxazolone (Christensen, Haase 2012). Either way, T cells promote the killing of 
haptenized cells and produce inflammatory cytokines like IFNγ and IL-4 thus promoting 
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further cellular infiltration to the site of inflammation and contributing to the characteristic 
edema (Kaplan et al. 2012).  
 
1.2.2 Atopic dermatitis  
Atopic dermatitis (AD) is a chronic, highly pruritic inflammatory skin disease which is 
often linked with the development of asthma and allergic rhinitis in early childhood. 
Clinical manifestations of AD include pruritus, cutaneous hyperreactivity, dry skin and 
recurring eczema, which usually start during early infancy or childhood. These symptoms 
can sometimes be accompanied by complications like food allergies, asthma, and/or 
allergic rhinitis during the first years of life, in a process called “atopic march” (Kubo et 
al. 2012). The prevalence of AD is increasing with currently 10-20% of children and 1-
3% of adults affected in developed countries (Larsen 2002). Continuous management of 
the conditions’ necessities poses an economic burden and recurring symptoms of AD 
like pruritus and itching creates a high social impact in sense by affect the patient’s 
quality of life. 
The pathogenesis of AD is not clearly understood but it appears to be a result of different 
genetic, epigenetic and environmental factors. Skin barrier abnormalities such as 
mutations in the FLG gene, which encodes the structural protein fillagrin, are risk factors 
in the predisposition towards AD (McAleer, Irvine 2013). A disrupted skin barrier leads 
to transepidermal water loss and renders the skin vulnerable for allergens and infectious 
agents.   
Innate and adaptive immune responses to the penetrating antigens play a major role in 
the pathogenesis of the disease. Patients with AD were found to be deficient in the 
production of antimicrobial peptides by keratinocytes (Kuo et al. 2013), making them 
prone to microbial colonization especially by Staphylococcus aureus.  
 
Immune responses in AD 
T cell responses in AD can be described as biphasic. Acute lesions are characterized by 
a Th2 predominant phenotype and increased expression of the Th2 cytokines IL-4, IL-5 
and IL-13 while chronic conditions are associated with a rise in the expression of IL-12 
and a switch to the Th1 phenotype (Fig. 2).  
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Exposure to allergen plays an important role in the exacerbation of AD. The immune 
mechanisms underlying AD are similar to those of asthma. Th2 cytokines IL-4, IL-5 and 
IL-13 are significantly increased in lesional and non-lesional skin in the acute phase of 
AD. IL-13 is known to be a major stimulator of inflammation and tissue remodelling at 
sites of Th2 inflammation (Mu et al. 2014), while IL-4 further promotes Th2 development.  
In addition, both IL-4 and IL-13 promote isotype switching in B cells to IgE and result in 
elevated circulating levels of IgE in most AD patients. Characteristic eosinophilia and 
macrophage infiltration in AD are mediated by IL-5 and GM-CSF, respectively. 
 
 
Figure 2. Immunologic pathways in the progression of AD (Leung DY. 2000). 
Patients with AD show a systemic Th2 response, elevated IgE levels and eosinophilia with low 
levels of Th2 cytokines in uninvolved skin. In acute lesions of AD, there is an increased infiltration 
of Th2 cells and increased expression of Th2 cytokines. The infiltration of macrophages and 
eosinophils increases the expression of IL-12 and lead to a switch in the immune response 
towards Th1. 
 
The Th2 phenotype is highly dependent on GATA3, the key regulator in the Th2 
differentiation program. Indeed, human studies revealed significantly higher mRNA 
expression of GATA3 in AD patients compared to healthy non-atopic individuals 
(Arakawa et al. 2004). GATA3 belongs to the GATA family of transcription factors and is 
expressed by a variety of immune cells including ILC2, NK cells, NKT cells and both 
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naïve and committed CD4+ T cells (Tindemans et al. 2014) (Fig. 3). It is also expressed 
by structural cells such as epithelial cells. In the skin, GATA3 is expressed in the 
keratinocytes of the epidermis and in the inner root sheath of the hair follicle (Chikh et 
al. 2007). 
Upon triggering of the T cell receptor (TCR) by antigen ligation, GATA3 expression is 
upregulated through IL-4-STAT6-mediated signalling. In the case of low dose antigen 
stimulation GATA3 expression is regulated in an IL-4 independent manner (Yamane et 
al. 2005).  The transcription factor GATA3 binds to the promotor at the Il4, Il5 and Il13 
genes and induces their transcription leading to increased Th2- cytokine levels. 
Increased levels of IL-4 lead to prolonged induction of growth factor indepent-1 (Gfi-1) 
through IL-4-STAT6 signalling (Zhu et al. 2002), which in turn promotes the expansion 
of GATA3- expressing cells (Zhu et al. 2006). In addition to driving Th2 polarization and 
proliferation, GATA3 inhibits the development of Th1 cells by different mechanisms such 
as inhibiting IL-12Rβ and STAT4 expression and silencing the Ifng gene (Wei et al. 
2011).  
   
 
 
Figure 3. Effects of GATA3 expression in different cells. 
 
Most recent, it has been shown that certain single nucleotide polymorphisms (SNPs) in 
the GATA3 gene are associated with an increased risk for the development of allergic 
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sensitisation (Huebner et al.) including allergic eczematous skin diseases like atopic 
dermatitis (Arshad et al. 2008). 
 
1.2.3 Psoriasis 
Psoriasis is a lifelong inflammatory skin disease which affects about 1-2% of adults 
around the world and is characterised by scaly, erythematous cutaneous plaques. 
Although it is considered an autoimmune disease, no autoantigens have yet been 
identified (Kupper 2003).    
Environmental factors like stress or trauma trigger psoriasis in genetically predisposed 
individuals. Keratinocytes initiate the process by producing self-DNA molecules that bind 
to the antimicrobial peptide LL37 and by releasing anti-inflammatory cytokines to activate 
DCs and enhance their antigen presenting activity. This results in the recruitment of T 
cells, mostly Th1 and Th17, to the skin and the production of different cytokines including 
IFNγ, TNF, IL-17a and IL-22. This cytokine milieu increases keratinocyte proliferation 
and stimulates the production of pro-inflammatory mediators and AMPs by keratinocytes, 
which sustains and amplifies chronic inflammatory disease processes (Nestle et al. 
2009).  
The Th1 response plays a major role in the pathogenesis of psoriasis, with IFNγ –
producing Th1 cells infiltrating the skin. These Th1 lymphocytes are responsible for the 
pathological reactions in psoriatic skin leading to keratinocyte hyperproliferation, small 
vessel proliferation and neutrophilic infiltration (Ghoreschi et al. 2003). Moreover, 
psoriatic patients with increased IFNγ serum concentration also showed increased 
expression of Tbet-mRNA in their PBMCs and a much higher Tbet/GATA3 ratio than in 
controls (Zhu et al. 2010).  
Tbet belongs to the Tbox family of transcription factors and is expressed in and 
functionally essential for different cells of the innate and adaptive immune system 
including DCs, NK cells, NKT cells, ILCs, CD4+ and CD8+ T effector cells, B cells, γδ T 
cells and a subset of T regulatory (TReg) cells (Lazarevic et al. 2013). However, Tbet is 
mostly known as the master regulator of the differentiation of Th0 cells to Th1 cells and 
the induction of the Th1 cytokine IFNγ.   Tbet expression is absent in naïve T cells and 
is first induced via TCR and IFNγR signalling through signal transducer and activator of 
transcription 1 (STAT1). The second wave of Tbet expression stabilizes the Th1 cell 
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phenotype and is induced by IL-12, functioning via STAT4 (Lazarevic et al. 2013). Tbet 
not only controls Th1 differentiation, it also induces the production of IFNγ by directly 
binding to regulatory elements at the Ifng locus, leading to changes in histone 
modification and enhanced Ifng transcription (Kanhere et al. 2012) as well as up-
regulation of IL-12Rb2 (Afkarian et al. 2002). Furthermore, it suppresses the Th2 cell 
lineage commitment by silencing the Il4 gene as well as repressing the binding of GATA3 
to Il5 promoter DNA (Kanhere et al. 2012). These functions of Tbet polarize the immune 
response towards Th1 making Tbet an important possible target for future therapies in 
autoimmunity and Th1-mediated diseases.   
 
 
Figure 4. Expression and functions of Tbet in immune cells (Lazarevic et al. 2013). 
 
1.3  Current strategies in the management of inflammatory skin diseases 
All of the skin conditions discussed above share symptoms and many aspects of the 
inflammation and therefore similar approaches are used in their treatment. Identification 
and elimination of allergic and inflammatory triggers as well as emotional stressors are 
most important in preventing the flares while application of moisturizers helps control the 
itch, reduces transepidermal water loss and minimizes the risk of infections in chronic 
conditions.  
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Anti-inflammatory and immunosuppressive therapies, including corticosteroids and 
calcinurine inhibitors, are used to control the inflammatory response resulting from 
immune system dysfunction in these diseases.  
Corticosteroid are the first–line treatment in skin diseases like AD and psoriasis and can 
range from low-potency topical application as maintenance therapy in chronic conditions 
to high-potency topical and/or systemic administration in severe cases. They act on a 
variety of immune cells carrying the glucocorticoid receptors (GR) including DCs, T 
lymphocytes, eosinophils, mast cells and macrophages. They suppress the transcription 
of genes encoding pro-inflammatory mediators such as IL-1α and IL-1β and enhance the 
transcription of anti-inflammatory genes, including inhibitors of nuclear factor-κB (IκBα), 
IL-1RII, annexin I, IL-10, and secretory leukocyte protease inhibitor (SLPI) (Holgate, 
Polosa 2008).  
 Long- term use of topical corticosteroids in chronic conditions, bears the risk of severe 
side effects including skin atrophy, striae, telangiectasia and acne (Walling HW 2010).  
Second-line treatment includes the use of topical calcineurine inhibitors (TCI) that act 
specifically on T cells. Calcineurine is responsible for the activation of the cytosolic 
nuclear factor of activated T cells (NFAT). Inactive NFAT cannot enter the nucleus to 
activate the transcription of cytokine-encoding genes. As a result, the production of 
inflammatory cytokines (IL-2, IL-4, IL-10 and IFNγ) as well as T cell proliferation is 
inhibited (Hultsch et al. 2005). Less conventional treatments include the use of tar 
preparations, UV therapy, and allergen immunotherapy.  
In recent years, there has been a growing interest in more specific therapies that target 
molecules involved in the elicitation of inflammatory skin diseases.  
Therapeutic antibodies especially those targeting cytokines that induce the inflammatory 
response have become an important class of drugs during the past two decades. For 
instance, several tumour necrosis factor (TNF) antagonists have already been approved 
for the treatment of plaque psoriasis (Chan, Carter 2010) in addition to the final clinical 
testing of IL-17A- and IL-23-specific antibodies in the treatment of this disease (Leonardi 
et al. 2012, Rich et al. 2013, and Papp et al. 2012). Moreover, the clinical effects of a 
monoclonal antibody that blocks both IL-4 and IL-13 have most recently been tested in 
patients with moderate to severe AD (Beck et al. 2014). Anti IgE antibodies are also 
being investigated in the treatment of atopic dermatitis with contradictory reports about 
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their efficacy especially in patients with elevated IgE serum levels (Vigo et al. 2006, 
Krathen, Hsu 2005).   
Recently, vitamin D deficiency is being increasingly linked to the development of allergic 
diseases (Muehleisen 2013). In addition, psoriatic patients were reported to have lower 
levels of vitamin D in comparison to healthy controls (Vähävihu et al. 2010). Therefore, 
oral vitamin D supplementation is proposed to have beneficial effects in AD by the 
upregulation of antimicrobial peptides and induction of Tregs (van der Aar et al. 2011). 
 
1.4  New therapeutic approaches using DNAyzme technology 
DNAzyme technology depends on the use of a specific family of anti-sense molecules 
called “DNAzymes” to inhibit the expression of a gene on mRNA level. As they are 
composed of DNA, DNAzymes are more active than ribozymes and are relatively easy 
to synthesize and handle, making them suitable promising candidates for therapeutic 
interventions. The function as well as present and possible future therapeutic 
applications of these molecules are discussed below.  
 
1.4.1 Molecular structure and mode of action 
DNAzymes (Deoxyribozymes) are single stranded, synthetic DNA molecules that 
comprise a cation-dependent catalytic core. They were first discovered in 1994 by 
Ronald Breaker and Gerald Joyce who reported that, using an in vitro selection 
technique, they were able to obtain a DNAzyme which catalysed the Pb2-dependent 
cleavage of an RNA phosphoester in a reaction processed with rapid turnover (Breaker, 
Joyce 1994). One year later, they generated Mg2+-dependent DNAzymes, which were 
able to cleave RNA with a high catalytic efficiency of kcat/Km ≈ 109 M-1*min-1 in conditions 
comparable to those of the intracellular environment (Breaker, Joyce 1995, Santoro, 
Joyce 1997). Further work resulted in the generation of the 10-23 family of DNAzymes, 
which consists of a catalytic core of 15 nucleotides and two substrate binding arms of 
variable length and sequence. These binding arms can specifically bind to 
complementary sequences on RNA through Watson-Crick base pairing. DNAzymes 
target and cleave mRNA in a Mg+2 –dependent manner through de-esterification between 
unpaired purine and paired pyrimidine residues (Santoro, Joyce 1997, Santoro, Joyce 
1998). Cleaved mRNA fails to be translated and is degraded after the dissociation of the 
DNAzyme. The DNAzyme itself binds to another mRNA molecule and the process is 
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started again (Fig. 5). The efficiency of DNAzymes in cleaving RNA is comparable to that 
of protein enzymes (Silverman 2005). 
 
Figure 5. mRNA cleavage by DNAzymes. 
1) DNAzymes binding to target mRNA. 2) Cleaving of mRNA. 3) Dissociation of DNAzymes and 
degradation of mRNA-cleavage products. 4) DNAzyme moves to the next mRNA molecule 
(Dissertation Tanja Dicke 2009). 
 
In order to use DNAzymes in in vivo applications, they need to be stabilized against 
nucleolytic degradation in body fluids. Several chemical modifications have been used 
to enhance DNAzyme biostability throughout the years. The most important and 
commonly used modification is the incorporation of a 3’-3’ inverted thymidine at the 3’-
end of the DNAzyme. The inversion creates a 5’-end on the 3’-terminus preventing 
exonuclease degradation and extending the half-life of DNAzymes from ≈70 minutes to 
over 21 hours in human serum. In addition, the reversion promotes stability of the 
DNAzyme during cellular uptake (Dass et al. 2002). Another modification is the 
phosphorothioate linkage replacing one of the non-bridging oxygens by sulphur. Even 
though this alteration reduces the action of endogenous nucleases, it is associated with 
toxicity and off-target effects. Locked Nucleic Acids (LNAs) are also used to modify 
DNAzymes. They comprise a 2′-O 4-C methylene bridge that locks in a C3′-endo 
conformation, thus increasing the binding affinity and activity of DNAzyems (Vester et al. 
2002, Schubert 2003).  The DNAzymes used in this study were modified by adding a 3’-
3’ inverted thymidine at the 3’-end to impart resistance to nuclease degradation. 
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1.4.2 Transcription factors as immunological targets for DNAzymes in    
inflammatory skin diseases 
Immune mechanisms involved in the pathogenesis of inflammatory skin diseases involve 
the recruitment of T cell subpopulations to mediate the inflammatory response. The 
contribution of these subtypes to the development of certain pathologies differs 
depending on the disease. In atopic dermatitis for example, Th2 cells predominate the 
acute phase and disrupt the Th1/Th2 balance by increased infiltration and production of 
Th2 cytokines such as IL-4, IL-5 and IL-13. This Th2 immune response is controlled by 
the transcription factor GATA3, which regulates the differentiation of Th2 cells and Th2-
cytokine production (Fig. 3). In a similar way, Th1 cells play the major role in the 
immunopathology of psoriasis with increased production of the Th1 cytokine IFNγ. The 
transcription factor Tbet, is, in this case, the orchestrator of such a response by among 
other effects controlling the differentiation and function of Th1 cells (Fig. 4) (Lazarevic et 
al. 2013). 
These central roles of GATA3 and Tbet make them interesting and promising targets for 
DNAzyme-treatment of AD and psoriasis. In fact, DNAzymes targeting GATA3 mRNA 
have been developed and their therapeutic potentials in murine models of asthma have 
already been demonstrated successfully (Sel et al. 2008).  
 
1.4.3 Drug delivery systems for dermal application of DNAzymes 
Although DNAzymes have been tested as therapeutic tools in different models including 
asthma and cancer (Sel et al. 2008, Mitchell et al. 2004), the use of these molecules in 
a dermal application can be challenging. The skin surface is compact with a natural flora 
of bacteria and fungi (Grice et al. 2008), producing great amounts of DNases and 
lowering the skin`s PH (Lambers et al. 2006), which can degrade or affect the DNAzymes 
activity before they even reach their targets. Another difficulty in this type of application 
is the necessity to transport these large, hydrophilic molecules through the skin 
compartment to the site of action, where they can encounter their target structure. To 
overcome these problems, Schmidts et al. developed a water-in-oil-in-water (w/o/w) 
multiple emulsion in which the DNAzymes with the inverted thymidine, were 
encapsulated in an inner aqueous phase. This aqueous phase was added to an oil phase 
and emulsified to obtain a water/oil (w/o) homogeneous emulsion, which was then 
dispersed in an aqueous phase containing a hydrophilic emulsifier to obtain the final 
w/o/w emulsion (Schmidts et al. 2011). 
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Figure 6. Water –oil- water emulsion. 
DNAzymes encapsulated in an inner water phase. These water droplets containing DNAzymes 
are suspended in an oil phase providing protection and better penetration into the skin. The oil 
phase itself is suspended in another water phase to obtain a w/o/w emulsion.  
 
This pharmaceutical formulation provided protection of the DNAzyme from degradation 
and the penetration enhancers added to this formulation facilitated a successful 
penetration into the skin. The DNAzyme uptake was higher when applying the 
formulation under gentle massage to help break down the oily membrane of the emulsion 
and release the DNAzymes from the inner phase (Schmidts et al. 2012). 
 
1.5 Hypothesis and Aims  
Inflammatory skin diseases cover a wide range of skin conditions that affect millions 
around the world. So far the treatment of most of these diseases depends on the use of 
glucocorticoids and other immune suppressive reagents that, despite their efficacy, have 
a diversity of side effects with severities ranging from mild to life-threatening and life- 
altering. The goal of this study was to examine the potentials of DNAzyme-based 
therapies in inflammatory skin diseases by targeting key transcription factors for the 
differentiation of T-helper cells.  
 DNAzymes against GATA3 and Tbet have already been established and GATA3-
specific DNAzymes have shown to be effective in the prevention and therapy of 
experimental models of allergic airway inflammation. The similarities in disease 
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pathogenesis between asthma and AD, in terms of the underlying Th2 phenotype, raised 
the question of whether GATA3-DNAzyme treatment will have similar promising effects 
in AD. Based on the same principle, we wanted to test the therapeutic potentials of Tbet-
specific DNAzymes on Th1-mediated inflammatory skin diseases.   
The first part of this project was to establish an animal model of allergic skin inflammation 
with a Th2 predominant phenotype comparable to that observed in AD. Thereafter this 
model was used to investigate the effects of GATA3-specific DNAzyme treatment on 
disease symptoms in vivo and on cellular and molecular level ex vivo. 
The second part involved the use of another modified model of inflammatory skin disease 
with a Th1-predominant phenotype and analysis of possible therapeutic effects of Tbet-
specific DNAzymes on disease symptoms in vivo and on cellular and molecular level ex 
vivo. 
We hypothesized that treatment with GATA3- or Tbet-specific DNAzymes can inhibit the 
specific Th-polarization towards a Th2 or Th1 –phenotype associated with inflammatory 
diseases and restore the normal Th1/Th2 balance, which make DNAzymes attractive 
target-specific therapeutic tools for the therapy of such skin conditions.  
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2 MATERIALS AND METHODS 
2.1  Animals  
Animals were kept in a specific pathogen-free environment in optimum temperatures of 
20 – 24ο C and a semi-natural light cycle of 12:12 hours light: dark.  
All experiments were conducted following protocols approved by the local authorities 
(Regierungspräsidium Giessen). For certain procedures mice were anesthetized by 
intraperitoneal (i.p.) injection of 200 μl of a Ketamine (76 mg/kg bw)/ Xylazin (10 mg/kg 
bw) mixture. 
Mouse strain Age Gender  Provider 
BALB/c 6-8 male Charles River 
DO11.10 8-10 male Marburg University 
    
 
 
 
2.2   Induction of skin inflammation in mice 
2.2.1  Oxazolone-induced dermatitis  
A combination of mechanical injury and the hapten oxazolone (4-Ethoxymethylene-2-
phenyl-2-oxazolin-5-one) were used to induce dermatitis in 6-8 week-old male BALB/c 
mice. The back skin (about 1 x 2 cm) of anesthetized mice was shaved using an 
electrical shaver followed by a razor. Skin injury was inflicted by tape stripping 5x with 
an ordinary adhesive tape. Mice were sensitized by epicutaneous application of 0.2% 
oxazolone (50 μl) dissolved in a 4:1 solution of acetone: olive oil. This first contact with 
oxazolone leads to the generation of oxazolone-specific T cells, and Th2 cells in 
particular.  
Three days later, skin was tape stripped again and inflammation was elicited by 
application of 0.2% oxazolone (50 μl) to the shaved skin. To assess the progression of 
inflammation, skin thickness was measured before challenge and on daily basis 
afterwards using a digital calliper (see 2.4.1). The control group was sensitized and 
Material /reagent  Provider 
Ketamine 50 mg/ml Inresa 
Xylazin (Ropmun®) 20 mg/ml Bayer 
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challenged with 50 µl acetone: olive oil (4:1). Mice were sacrificed three days after 
challenge to collect samples for ex vivo analysis (Fig. 7A).  
 
 
2.2.2  OVA / CFA-induced dermatitis  
In this model, 8-10 weeks old-male DO11.10 mice were sensitized to the protein antigen, 
ovalbumin (OVA). 75 μg of OVA (grade V) were dissolved in phosphate buffered saline 
(PBS) and then emulsified in complete Freund’s adjuvant (CFA, 50% vol / vol). 100 μl of 
the emulsion were subcutaneously (s.c.) injected into the loose skin of each side of the 
inguinal area (lower left and lower right area of the abdomen). Seven days later, mice 
were challenged on three consecutive days by epicutaneous application of 50 μl of 20% 
OVA (dissolved in a 10% dimethyl sulfoxide, DMSO, solution to enhance skin 
permeability). 
A control group was sham sensitized by subcutaneous injection of PBS emulsified in 
CFA and challenged with 10% DMSO alone. Skin thickness was measured before and 
then daily after challenge to assess progression of inflammation. Mice were sacrificed 
four days following challenge and samples were collected for ex vivo analysis (Fig. 7B). 
Material Provider 
Ovalbumin Grade V Sigma-Aldrich 
Complete Freund’s adjuvant (CFA) Sigma-Aldrich 
Phosphate buffered saline (PBS) Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) Roth 
Discofix®3-way stopcock Braun 
 
Material  Provider 
Electrical shaver QT4022 Philips 
Razor Wilkinson sword 
Oxazolone Sigma-Aldrich 
Olive oil Sigma-Aldrich 
Acetone  Roth 
Adhesive tape  Schöngene® plast 
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Figure 7. Protocols for induction of skin inflammation. 
(A) Oxazolone-induced dermatitis, (B) OVA/CFA-induced dermatitis.  
 
2.3  Treatment protocols for topical application of DNAzymes in vivo 
2.3.1 DNAzymes and controls used for topical application in vivo 
To ensure a better penetration and delivery of DNAzymes through the skin, they were 
used in a form of a w/o/w multiple emulsions prepared in collaboration with the “Technical 
hochschule mittelhessn,THM” as described in (1.4.3) and in (Schmidts et al. 2011). 
Briefly, hgd40 (GATA3-DNAzyme) or td32 (Tbet-DNAzyme) were encapsulated in an 
inner water phase, which was then emulsified with an oil phase until a homogenized w/o 
emulsion was obtained. This emulsion was later dispersed in another aqueous phase to 
achieve the final w/o/w emulsion. Similarly, another w/o/w emulsion containing control 
DNAzyme named ODNg3, which has an active catalytic domain and a non-specific 
sequence in the binding arms, was also used in the study. To eliminate any formulation-
related effects, both placebo (no active ingredient) and Dexamethasone were also 
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formulated in w/o/w emulsion.  
2.3.2 Prophylactic treatment of oxazolone- induced dermatitis with hgd40 
Skin inflammation, was induced in mice using oxazolone as described in paragraph 
(2.2.1). For the prophylactic treatment, the back skin of mice in each different treatment 
group (see table 1) was treated by applying and gently massaging 50 μl of the respective 
emulsion. This process was conducted once daily starting one day before sensitization 
until the day before termination (Fig. 8A). On challenge day, mice were treated with the 
emulsion in the morning and challenged later in the afternoon. The skin was wiped with 
acetone before challenge to eliminate any emulsion residues on the skin surface. 
Table 1. Groups in the prophylactic treatment of oxazolone-induced dermatitis 
Group Sensitization Challenge Treatment 
1 Solvent Solvent Placebo 
2 0.2% Oxazolone 0.2% Oxazolone Placebo 
3 0.2% Oxazolone 0.2% Oxazolone 0.4% ODNg3 
4 0.2% Oxazolone 0.2% Oxazolone 0.4% hgd40 
5 0.2% Oxazolone 0.2% Oxazolone 2% hgd40 
6 0.2% Oxazolone 0.2% Oxazolone 0.1% Dexamethasone 
 
2.3.3 Semi-therapeutic treatment with hgd40 in oxazolone-induced 
dermatitis  
Inflammation in the skin was elicited as already mentioned in paragraph (2.2.2). For the 
semi-therapeutic treatment, 50 μl of the respective emulsion were topically applied to 
the shaved back once daily starting one day before the challenge (day-1) until the day 
before termination (Fig.  8B). On challenge day, mice were treated with the emulsion in 
the morning and challenged later in the afternoon to allow time for absorption through 
the skin. The skin was wiped with acetone before challenge to eliminate any emulsion 
residues on the skin surface that may interact with oxazolone. 
2.3.4 Preventive treatment with a Tbet-specific DNAzyme in OVA/CFA-
induced dermatitis 
 For the induction of skin inflammation, mice were sensitized and challenged as 
described in paragraph (2.2.2). For the preventive intervention, 50 μl of the respective 
emulsion were topically applied twice a day with a 12-hour interval. The first treatment 
started one day before challenge and continued twice/day until 12h before termination 
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on day 3. Skin thickness was measured on a daily basis to monitor the inflammation 
progress. Several hours were left between treatment and OVA challenge to allow 
enough time for proper absorption of the emulsion. In addition, skin was wiped with 
acetone before challenge to avoid any interaction between the emulsion component and 
OVA in the challenge process.  
* [dT-rev-Q]: inverted thymidine on the 3´end.  
**Technische Hochschule Mittelhessen 
 
Table 2. Groups in the semi-therapeutic treatment of oxazolon-induced dermatitis. 
 
Table 3.Treatment groups in the OVA/CFA model. 
 
Materials Provider  
hgd40 Oligonucleotide 5´to 3´ 
GTGGATGGAGGCTAGCTACAACGAGTCTTGGAG[dT-rev-Q]* 
 
Biospring 
ODNg3 Oligonucleotide 5´to 3´ 
CCATGTGGAGGCTAGCTACAACGACTGGAATCA[dT-rev-Q]* 
 
Biospring 
Td32 Oligonucleotide 5´to 3´  
CTCCCGGAAGGCTAGCTACAACGACCTTTGGCA[dT-rev-Q]* 
 
Biospring 
Dexamethasone Sigma-Aldrich 
All w/o/w emulsions  THM ** 
Group Sensitization Challenge Treatment 
1 Solvent Solvent Placebo 
2 0.2% Oxazolone 0.2% Oxazolone Placebo 
3 0.2% Oxazolone 0.2% Oxazolone 0.4% ODNg3 
4 0.2% Oxazolone 0.2% Oxazolone 2% ODNg3 
5 0.2% Oxazolone 0.2% Oxazolone 0.4% hgd40 
6 0.2% Oxazolone 0.2% Oxazolone 2% hgd40 
7 0.2% Oxazolone 0.2% Oxazolone 0.1% Dexamethasone 
Group Sensitization Challenge Treatment 
1 OVA/CFA 20% OVA Placebo 
2 OVA/CFA 20% OVA 0.4% ODNg3 
3 OVA/CFA 20% OVA 0.4% td32 
4 OVA/CFA 20% OVA 0.4% hgd40 
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Figure 8. Treatment protocols of skin inflammation with DNAzymes. 
(A) Prophylactic treatment protocol of oxazolone-induced dermatitis. (B) Semi-therapeutic 
treatment of oxazolone-induced dermatitis. (C) Semi-therapeutic treatment of OVA/ CFA-induced 
dermatitis. 
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2.4  In vivo assessment of skin inflammation 
 Skin thickness measurement  
The changes in skin permeability during inflammation result in edema formation. This in 
turn is reflected by characteristic increase in skin thickness which can be measured as 
an indicator of disease severity. In our animal models skin thickness was measured 
throughout the experiment to monitor inflammation progression in vivo. A skin fold was 
formed in the middle of the inflamed site along the head-to-tail axis and skin fold 
thickness was measured in the center of the treatment area using a digital caliper 
(Bochem, Germany) with an accuracy of +/- 0.03 mm and a resolution of 0.01 mm. Skin 
thickness on the day of challenge day 0 was used as a baseline and deviation of skin 
thickness to day 0 (skin thickness day x – skin thickness day 0) was calculated in each 
animal for every day after challenge including termination day. All measurements were 
conducted on anesthetized mice.  
 
2.5  Animal sacrifice and sample collection 
Animals were sacrificed by intraperitoneal injection of 200 µl of 5x anaesthesia solution. 
Once the animal has stopped breathing and showed no more reflexes (eye lids, paws), 
the shaved piece of dorsal skin was surgically removed while maintaining orientation of 
the tissue, anterior to posterior. The obtained skin sample was then cut into three pieces 
with similar sizes and tissue orientation. One piece was transferred into a cryotube, snap 
frozen in liquid Nitrogen and stored at -80°C for further processing (see next section on 
Tissue lysis and RNA isolation). Each of the other two pieces were placed on a histology 
cassette with epidermis facing up and skin oriented anterior to posterior. One cassette 
was emerged in 6% Paraformaldehyde and the other in zinc fixative for histological 
analysis (see section 2.7). 
 
2.6  Gene expression analysis  
2.6.1 Tissues lysis and RNA isolation 
Frozen skin samples were weighed and ground to fine powder using mortars previously 
cooled in liquid Nitrogen. The powder was homogenized in 1 ml Trifast lysis buffer/100 
mg tissue. This suspension was next passed through a 0.9 mm syringe needle for 4 
times to further disrupt the cells and then transferred to 1.5 ml RNase-free tube. After 
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short incubation (about 5 min) at RT, the suspension was centrifuged at 12000 g for 10 
min at 4° C and the supernatant was collected. 200 µl chloroform were vortexed with the 
supernatant and then incubated for 5 min at RT. Next, the mixture was centrifuged at 
12000 g for 5 min at 4° C and the upper aqueous phase containing the RNA was 
collected. To precipitate the RNA, the aqueous phase was mixed with 0.5 ml isopropanol 
and incubated for ≥ 15 min either on ice or at 4° C and then centrifuged at 12000 g for 
10 min at 4○ C. After discarding the supernatant, the RNA pellet, having a gel-like 
appearance, was washed twice with 1 ml 75% ethanol and finally dissolved in 50 µl 
RNase-free water. 
Material  Provider 
peqGOLD TriFast TM Peqlab 
Trichlormethan / Chloroform Roth 
2-Propanol / Isopropanol Sigma - Aldrich 
Ethanol 100% molecular biology grade Sigma - Aldrich 
RNase-free water Qiagen 
Needle  BD 
Cryo-tubes 1.7ml Sarstaedt 
Safe seal® tubes 1.5 ml  Carl Roth  
Micro 200R Centrifuge  Hettich 
 
2.6.2  RNA clean-up and on column DNA digestion 
To obtain a highly purified RNA, RNA clean-up using RNeasy mini spin columns was 
performed according to manufacturer’s instruction. The volume of the RNA sample was 
increased to 100 µl using RNA-free water. Next, 350 µl RLT buffer and 250 µl 96% 
ethanol were added and the whole 700 µl were transferred to RNeasy mini spin columns 
and centrifuged at 8000 g for 1 min at RT. The high salt content of the RLT buffer allows 
binding of the total RNA only to the RNeasy silica membrane while ethanol improves the 
binding conditions. After RNA-binding all other contaminants were washed away by the 
addition of 350 µl washing buffer RW1 and centrifugation for one minute at 8000 g at 
RT.  
To eliminate any possible contamination with DNA, a DNA digestion was also performed 
on the RNeasy mini spin columns using the RNase-free DNase set ®. After the first 
washing steps in RNA clean-up as described above, 80 µl of a mixture of DNase I and 
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RDD buffer (10 µl DNase I and 70 µl RDD buffer) was added to the spin column 
membrane and incubated at RT for 15 min. The DNase I was removed during 
subsequent washing steps with RW1 and RPE buffers and RNA elute was obtained by 
the addition of 30 µl RNase-free water to the spin column membrane followed by 
centrifugation for 1 min at 8000 g. 
Material Provider 
RNeasy® mini kit Qiagen 
RNase-Free DNase® Set Qiagen 
 
2.6.3  RNA quantitation and quality assessment 
2.6.3.1  RNA quantitation 
 RNA concentration was determined using a NanoDrop 2000c spectrophotometer 
(Thermo scientific). 1 μl of the RNA sample was retained in place via surface tension 
between two fibre optic cables and the absorbance was measured at two wave lengths, 
260 nm where the RNA absorbs and 280 nm at which protein and phenol absorb. Based 
on the 260 / 280 ratio the RNA purity was assessed. A ratio between 1.8- 2 was regarded 
as “pure” RNA.   
2.6.3.2  RNA quality assessment  
The overall quality of the RNA was assessed by gel electrophoresis. All equipment, 
including electrophoresis chamber, gel form and combs were washed with RNase Zap 
to create an RNase-free working environment. To prepare the samples, a mix of 1 μg 
RNA, 5 μl RNase-free water and 5 μl RNA-sample buffer was incubated at 65○ C for 10 
min then placed directly on ice. Samples as well as a RNA ladder were then loaded on 
a 2% agarose gel containing 5 μl ethidium bromide. The gel was run for an hour at 100 V 
in Tris Acetate EDTA (TAE) buffer. 
For mammalian total RNA, two intensive bands, representing the 28S and the 18S of 
the ribosomal RNA, but no degradation products should be observed. 
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Material  Provider 
 2x RNA sample loading dye Peqlab 
High range RNA ladder  Peqlab 
Tris Acetate EDTA (TAE) Sigma 
Ethidium bromide solution 0.07% AppliChem 
Universal RNase-free Agarose  Peqlab 
RNase zap  Ambion 
Fusion FX7TM system Peqlab 
Fusion-capt software Peqlab 
 
2.6.4  Reverse transcription  
In this procedure the isolated RNA was reverse transcribed to obtain first-strand cDNA 
using the Omniscript® kit. Oligo dt primers, which hybridize to the poly A tail of mRNA, 
were added to the reaction to provide a transcription starting point for the polymerases. 
The reaction mix was prepared as detailed below and reverse transcription was 
performed in a 3-step- procedure using a Biometra TRIO-Thermo block. During the first 
step the reaction mix was incubated for 1 hour at 37○ C followed by a degradation step 
of 5 min at 93○C to stop transcription. In the final step the reaction was cooled to 4○C.  
Reaction mix:  
X μl      RNA (500 ng) 
 2  μl     10x RT-Buffer 
 2  μl      dNTP 
 1  μl      Oligo-dt 18 primer 
 1  μl      Omniscript reverse transcriptase   
 Y μl      RNase-Free water  
 20 μl     End volume 
 
 
Material Provider 
Omniscript ® RT Kit Qiagen 
Oligo dt 18 Primer Metabion  
TRIO-Thermo block Biometra 
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2.6.5  Real time polymerase chain reaction (RT-PCR) 
Expression levels of different genes were analysed using real time quantitative PCR. 
The cDNA obtained from the reverse transcription was amplified using a pair of primers 
for the gene of interest and the QuantitTectTM SYBR®Green-Kit (containing a mixture of 
Taq ploymerases, dNTP, PCR buffer and SYBR Green I dye). The reaction was 
performed in RotorGene3000 which simultaneously enables quantification of the target 
gene by detecting fluorescence of the SYBR Green dye I bound to the amplified double 
strand DNA.   
Because the SYBR Green I dye used in the reaction binds to any double stranded DNA 
including any genomic DNA contaminating the sample, all primers were designed to 
flank at least one intron. This allows the discrimination between products amplified from 
cDNA and those amplified from genomic DNA based on the size of products. 
In addition, GATA3 primer also designed to flank the region where the DNAzyme 
catalyses the mRNA, to ensure that no degradation products of the targeted RNA, but 
only intact non-catalysed RNA is amplified  
The PCR reaction was set as shown below: 
5      μl     QuantitTectTM SYBR®Green master mix 
0.25 μl      Forward primer (10 pMol)  
0.25 μl      Reverse primer (10 pMol)  
4.5   μl      cDNA (0.5 μg) 
10    μl      end volume 
 
The tubes were then loaded into the RotorGene 3000 and ran for 40 cycles under the 
following cycling profile: 
Activating Polymerases  95○C 15 min  
Denaturation  94○C 15 sec  
40 cycles Annealing  Primer Tm  30 sec  
Extension  72○C 30 sec 
 
The gene expression was normalized to the housekeeping gene ribosomal protein L32, 
which was included in each PCR run. Housekeeping genes are usually expressed on 
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constant levels in pathologic and non-pathologic conditions and are used as internal 
controls in RT-PCR. The relative mRNA expression was calculated to a reference 
sample. The reference was generated as follows: The cDNA from one skin sample was 
used as a template in several different PCR reactions, each performed to amplify a 
different gene of interest. The different PCR products were then diluted to obtain a 
specific amount of each gene of interest (reflected by cycle threshold number Ct). The 
reference was used to compare and normalize all individual runs within one experiment 
and all individual experiments of the same model. Therefore, it was also included into 
each PCR run.  
Table 4. List of primers used in the RT-PCR. 
 
Relative mRNA expression was calculated using the equations listed below:  
ΔCt sample = Ct target gene sample - Ct L32 sample  
ΔCt reference = Ct target gene reference - Ct L32 reference  
ΔΔCt = ΔCt sample - ΔCt reference          
Relative gene expression = 2-ΔΔct 
Relative gene expression (%) =  
Relative gene expression sample / mean relative gene expression placebo x 100 
Gene Primer Sequence     Tm Product size 
L32 For: 5’-GCA AGT TCC TGG TCC ACA AT -3’   
Rev: 5’-GGG ATT GGT GAC TCT GAT GG -3 
 
58○ C 
 
152 bp 
GATA3 For:  5’-ACG GAA GAG GTG GAC GTA CT -3’ 
Rev: 5’-CGC CAG AGA GGA TGA AG -3’ 
 
60○ C 
 
297 bp 
IL-4 For:  5’-TCA ACC CCC AGC TAG TTG -3’ 
Rev: 5’-TGT TCT TCG TTG CTG TGA -3’ 
 
60○ C 
 
177 bp 
IFNγ For:  5’-GCT TTG CAG CTC TTC CTC AT -3’ 
Rev: 5’-GCA GGA TTT TCA TGT CAC CA -3’ 
 
58○ C 
 
175 bp 
Tbet 
 
For:  5’-AGG TGT CTG GGA AGC TGA GA -3´ 
Rev: 5`- CCA CAT CCA CAA ACA TCC TG -3 
 
60○ C 
 
174 bp 
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2.7  Histology 
Specimens from the sensitized and treated skin area were placed in embedding 
cassettes with the epidermis facing up. The whole cassettes were immersed in either a 
Zinc or a 6% paraformaldehyde (PFA) fixative fluid for 24-48 h. Zinc fixation allows 
preservation of the tissue and cells as they naturally occur and prevents autolysis by 
coagulating and hence deactivating lysosomal enzymes. PFA, on the other hand, reacts 
with primary amines on proteins and nucleic acids to form partially-reversible methylene 
bridges.  
After removal from the fixative, samples were washed with water and then dehydrated 
by transferring the cassettes into a series of alcohol-water solutions (70%, 96% and 
100% ethanol). 
The alcohol was then replaced with Roticlear® (Xylol substitute) and samples were finally 
embedded into paraffin blocks. Using a microtome, 5 μm sections were made from the 
paraffin blocks and mounted onto microscope slides.  
Material Provider 
Zinc fixative  BD pharmingen 
6% Paraformaldehyde (PFA) Merck 
Ethanol absolute, 96%, 70% Otto Fischar  
Roticlear® Roth 
Microm HM 355S TM Thermo scientific  
Microscope slides  Thermo scientific  
Cassettes  Engelbrecht 
 
Material Provider 
QuantitTectTM  SYBR®Green Qiagen 
RotorGeneTM Corbett Research 
Primers  Metabion 
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2.7.1  Haematoxylin and eosin staining  
This staining was used to provide a general overview of the skin structure and of the 
cellular influx into site of inflammation.  
The H&E staining uses two different dyes, haematoxylin which is a combination of the 
haematin dye and aluminium ions (AL3+) giving it a positive charge. Therefore, 
haematoxylin binds to the negatively charged chromatin in the nucleus and stains it 
purple-blue. Eosin, on the other hand, is a negatively charged pink dye that binds to the 
positively charged structures including the proteins in the cytoplasm and connective 
tissues.  
For staining, paraffin was removed by 20 min incubation in Xylol. The sections were then 
rehydrated by washes in a series of gradient alcohol (100%, 96%, 70%) and finally 
water. After the deparaffinization and rehydration, sections were stained in Gill’s 
Haematoxylin No.2 for 10 min. The excess dye was discarded by washing with running 
water for 10 min followed by washing with distilled water. Next, sections were stained in 
eosin for 5 min followed by washing with distilled water.  
After staining, sections were dehydrated through a gradient alcohol series (70%, 96% 
and 100%) and cleared in roticlear, then covered with cover slips using the mounting 
medium Entellan® for adhesion. 
 
Material Provider 
Roticlear ® Roth 
Ethanol absolute, 96%, 70% Otto Fischar  
Gill’s Hematoxylin No.2 Merck 
Eosin G  Merck 
Entellan® Merck 
Cover slips  Thermo scientific 
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2.7.2 Immunohistochemistry 
Surface protein markers are used as targets for antibodies to stain certain cells within 
the tissue section. A specific staining for CD4+ cells and GATA3 in skin sections was 
performed with the help of Dr. Ulrich Purath.  
Sections were deparaffinised and rehydrated by immersing in roticlear® and a series of 
gradient alcohol and finally in distilled water as previously described (2.7.1). To make 
the epitopes available for antibody binding, an antigen retrieval procedure was 
conducted. For this purpose, slides were immersed in a preheated, citrate-based 
unmasking retrieval solution (pH= 6.0) and then heated in a pressure cooker for 40 min. 
When the pressure marker went off, the slides were removed and washed in PBS for 10 
min. Next, endogenous peroxidase activity was blocked with a hydrogen peroxidase 
(H2O2) solution (1 ml 30% H2O2 in 50 ml PBS) for 15 min in the dark and then washed 
in PBS for 10 min. Sections were then incubated with horse serum for 30 min to block 
unspecific binding. After the serum was removed (without washing) sections were 
stained either for CD4 or GATA3.  
For CD4 staining, sections were incubated with the primary antibody (anti CD4 1:400 in 
PBS) at RT for one hour. The primary antibody was rinsed off with PBS and sections 
were incubated for 20 min with the ImmPRESSTM reagent containing the secondary 
antibody (anti-rabbit Ig) coupled with peroxidase. After a washing step with PBS, few 
drops of DAB were added to the sections. DAB is rapidly oxidized by the highly active 
peroxidase micro polymers attached to the secondary antibody. This forms a stable 
brown precipitate to detect the epitope specific antibody binding. Sections were finally 
washed with tap water, dehydrated in a series of gradient alcohol (70%, 96% and 100%) 
and roticlear® then mounted in Entellan®.  
For GATA3 staining, sections were incubated with the primary antibody (anti GATA3 
1:300) for one hour, washed with PBS and then incubated for another 20 min with the 
ImmPRESSTM   anti mouse-Ig complex. The signal was detected by addition of DAB 
substrate. Sections were finally washed, dehydrated and eventually mounted in 
Entellan®. 
For quantification of positively stained cells, each section was divided into 3 equal parts 
and a high power field was chosen in each part. Positive signals were counted per high 
power field and averaged for all sections of the same treatment group. Hair follicles and 
upper layers of the epidermis were excluded from the quantification.  
2. MATERIALS AND METHODS 
38 
 
Material Provider 
Rabbit polyclonal anti- CD4  Novus Biologicals 
Mouse monoclonal anti- GATA3   BD-Pharmingen 
ImmPRESS Anti-Rabbit Ig Polymer Detection Kit Vector labs 
ImmPRESS Anti-mouse Ig Polymer Detection Kit  Vector labs 
Impact DAB Vector labs 
Normal horse serum blocking solution Vector labs 
Low PH citrate- based antigen masking solution   Vector labs  
30% H2O2  Roth 
PBS  Sigma-Aldrich  
Pressure cooker  Highlights  
 
2.8  Statistical analysis 
Data analysis and graphing was conducted using the software GraphPad Prism, version 
6 ®. In each group the mean value ± standard error of the mean was used in the bar 
graphs. Statistical differences were determined by student’s t test (between 2 groups), 
one-way analysis of variance (ANOVA) (between multiple groups) or two-way analysis 
of variance (ANOVA) (between multiple groups over multiple time points). A p value of 
smaller than 0.05 (p ≤ 0.05) was considered to indicate statistical significance.  
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3  RESULTS 
3.1  Establishment of an oxazolone-induced contact dermatitis model  
The first goal of this work was establishing an animal model of allergic skin inflammation 
with a predominant Th2 immune response. For this reason, we used oxazolone, a hapten 
known to skew a mixed phenotype with a higher influx of Th2 cells, to induce a subacute 
prolonged contact hypersensitivity reaction in BALB/c mice as described in section 
(2.2.1). Briefly, the shaved back skin of mice was tape-stripped 5x, to mimic skin injury 
caused by scratching in patients with AD, and sensitized by epicutaneous application of 
oxazolone to induce oxazolone-specific T cells. Three days later, mice were tape 
stripped and challenged the same way to elicit an allergic skin inflammation (Fig. 7A). 
Three days following challenge, samples were collected for ex vivo analysis. 
The release of inflammatory mediators during the allergic inflammatory reaction changes 
skin permeability. This along with infiltration of inflammatory cells into the site of 
challenge lead to the formation of the characteristic edema noted in allergic skin 
inflammation, which is usually reflected by increased thickening in the skin. Thus, daily 
skin thickness measurements were used as a parameter to monitor disease progression 
in vivo. 
As our data clearly shows, in mice sensitized and challenged with oxazolone there was 
a progressive increase in skin thickness in the days following oxazolone challenge. Skin 
thickness doubled within the first 24 h after challenge and continued to increase until 
termination on day 3 (Fig. 9). Such an effect was absent in the control group which was 
sham sensitized and challenged with solvent only. The skin thickness in this group 
remained unchanged throughout the experiment with values similar to those measured 
on the day of challenge. The differences in skin thickness between these two groups 
were significant during the experiment.   
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Figure 9. Oxazolone induced a progressive thickening of the skin. 
The back skin of mice was tape stripped and mice were sensitized and challenged with either 
solvent or oxazolone as described in (2.2.1). Skin thickness was measured on days 0, 1, 2, and 
3 and deviation to day 0 was calculated. Data are compiled from 4 separate experiments (n= 6-8 
per group/experiment) and are shown as mean ± SEM. Significant differences are marked 
*p˂0.05, **p˂0.01 and ***p˂0.001 compared to solvent at the same time point. 
 
 
To examine histological changes and cellular influx, skin samples were prepared for 
histology as described in (2.7) and sections were stained with H&E (2.7.1). 
 Histological analysis revealed mild epidermal and dermal thickening, edema formation 
as well as a prominent cellular infiltrate into the dermis in sections of lesional skin 
samples obtained from oxazolone challenged mice. The inflammatory infiltrate 
accumulated in the upper part of the dermis and around the small capillaries in the skin. 
In the solvent group no signs of skin inflammation were noted. There was a minor 
disruption in the epidermis, probably due to tape stripping, while no prominent changes 
were observed in the dermis. Moreover, no increase in the dermis thickness nor an 
accumulation of inflammatory cells at the site of challenge was noted (Fig. 10). These 
findings support the results obtained from skin thickness measurement.  
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Figure 10. Oxazolone- induced dermatitis was characterized by epidermal thickening and 
cellular infiltration. 
Skin sections from oxazolone or solvent-challenged mice were stained with H&E and examined 
at a 100X magnification. There was a clear infiltration of cells into the site of inflammation after 
challenge with oxazolone.  
 
In the literature, oxazolone-induced dermatitis has been described to have a Th1-
dominant, a mixed Th1/Th2 or a Th2-dominant phenotype (Dearman et al. 1994, 
Thomson et al. 1993, Kusumoto et al. 2007). To investigate the phenotype in this model, 
RNA was isolated from inflamed skin (2.6.1), reverse transcribed (2.6.4) and the relative 
expression of Th1 and Th2 related transcription factors and major cytokines in the skin 
was quantified using RT-PCR (2.6.5). 
Our data showed that skin injury and oxazolone-challenge resulted in a significant 
increase in the mRNA expression of GATA3, the main transcription factor in Th2 cell 
differentiation. In addition, the expression of the Th2 cytokine IL-4 in the skin was also 
significantly increased in the oxazolone-challenged group (Fig. 11). 
No significant changes in the expression of the Th1 cytokine IFNγ or the transcription 
factor Tbet were detected. There was only a tendency of an increased IFNγ and a 
decreased Tbet expression.  
These results suggest that oxazolone elicited a progressive allergic inflammatory 
response in the skin with a Th2-predominant phenotype.  
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Figure 11. Increased mRNA expression of Th2- related genes in the skin upon oxazolone 
challenge. 
Skin samples were collected on day 3 after challenge and mRNA expression in the skin was 
quantified using RT-PCR after normalization to the house keeping gene L32 and a reference 
sample. Data are compiled from two separate experiments (n= 6-8 group/experiment) and are 
shown as mean ± SEM. Significant differences are marked *p ≤ 0.05 compared to solvent. n.s: 
not significant.  
 
3.2  Effects of a GATA3-specific DNAzyme on oxazolone-induced 
dermatitis in vivo 
In this part of the study, several experiments were conducted using the oxazolone model 
to test the effects of treatment with the GATA3-specific DNAzyme hgd40 on disease 
progression. Two preventive approaches were used for treatment. In the prophylactic 
approach DNAzyme treatment started before the sensitization. For “semi-therapeutic” 
treatment mice were left untreated during the sensitization phase and first treatment 
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started 24 h before oxazolone challenge. The GATA3-specific DNAzyme was formulated 
in a special w/o/w emulsion designed to protect the DNAzyme against degradation and 
to enhance skin penetration. In addition to the hgd40 treated groups, several treatment 
control groups were included in these experiments. To discriminate between the placebo 
and specific DNAzyme effects, a placebo control group treated with the designed 
emulsion without DNAzyme was analyzed. In addition, another group treated with an 
emulsion containing the control DNAzyme (ODNg3) was also included in the study to 
assess the biological specificity of hgd40. This control DNAzyme has an active catalytic 
domain while the nucleotides in the binding arms are scrambled to create a non-specific 
sequence. As a positive treatment control, the corticosteroid dexamethasone was used 
in a similar w/o/w formulation. To evaluate the oxazolone-induced allergic inflammatory 
response, a control group was sham sensitized and challenged with solvent and treated 
with placebo. This group was compared directly to the placebo-treated oxazolone-
challenged group. 
 
3.2.1 Effects of prophylactic treatment with GATA3-specific DNAzyme 
hgd40 on disease progression  
The efficacy of the GATA3-specific DNAzyme hgd40 was investigated in the oxazolone 
model. As described earlier, male BALB/c mice were tape-stripped, epicutaneously 
sensitized with oxazolone and similarly challenged three days later. For the prophylactic 
approach, mice were first treated one day before the sensitization and the treatment 
continued once daily until day 2 after challenge (Fig. 8A). 50 µl of the emulsion containing 
either 0.4% or 2% hgd40 were applied to the skin and gently massaged to help release 
the active ingredient from the inner phase of the w/o/w emulsion. Control groups were 
treated with either placebo, ODNg3 or dexamethasone. A detailed description of the 
different groups can be found in table 1 section 2.3.1. 
Throughout the experiment, skin thickness was measured on a daily basis to monitor 
disease progression and the allergic inflammatory response in vivo. At the end of the 
experiment on day 3 skin samples were collected from sacrificed mice for ex vivo 
analyses.  
 
3.2.1.1  Effects of DNAzyme treatment on skin swelling  
Skin measurements showed that one day after oxazolone challenge, skin thickness was 
significantly increased in all oxazolone-challenged groups compared to the solvent-
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challenged group. This increase continued until termination day in the placebo and 
control DNAzyme (ODNg3)-treated groups. In both hgd40-treated groups showed a 
significant reduction in skin thickness on days 2 and 3.  Mice treated with dexamethasone 
had a significantly thinner skin upon treatment and throughout the experiment. The skin 
thickness of the dexamethasone group was even lower than in the solvent group on days 
2 and 3 (Fig. 12), indicating possible adverse effects of skin thinning usually associated 
with topical corticosteroids. 
 
 
Figure 12. Effects of hgd40 prophylactic treatment on skin thickness in oxazolone-induced 
dermatitis. 
BALB/c mice were sensitized, challenged and treated as mentioned in (2.3.1). Skin thickness was 
measured on days 0, 1, 2, 3 post challenge and deviation to day 0 was calculated. Data are 
compiled from 3 different experiments (n= 6-8 per group/ experiment) and are shown as mean ± 
SEM. Significant differences are marked *p ≤ 0.05, ***p ≤ 0.001 (compared to placebo + Oxa) 
and #p ≤ 0.05, ##p ≤ 0.01, ###p ≤ 0.001 (compared to ODNg3 + Oxa). 
 
In summary, in vivo observations revealed significant treatment effects of hgd40 on the 
manifestation of oxazolone-induced dermatitis reflected in a reduced thickening in the 
skin after treatment.  
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3.2.1.2  Effects of DNAzyme treatment on cellular infiltration  
Skin swelling associated with contact hypersensitivity is a result of the allergic 
inflammatory process in the skin including the formation of edema and widening of 
intracellular spaces in addition to the infiltration of cells into the site of inflammation.  
To assess the features of oxazolone-induced dermatitis and changes in the 
histopathology due to different treatments, skin sections were examined after H&E 
staining.  
Histological analysis showed a characteristic but mild epidermal thickening and a 
substantial infiltration of inflammatory cells after oxazolone challenge. However, no 
significant changes in the density of cells infiltrating the dermis were observed neither in 
the 0.4% nor the 2% hgd40 treated groups compared to placebo or control DNAzyme  
ODNg3 groups. In contrast, this cell infiltration was strongly restrained in the 
dexamethasone group (Fig. 13). 
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Figure 13. Prophylactic treatment with hgd40 had no significant effect on dermal cell 
infiltration. 
Skin samples were collected on day (+3) and sections from different treatment groups were 
stained with H&E and examined at 100x magnification. All oxazolone-challenged groups showed 
comparable epidermal thickening and cellular infiltration except the dexamethasone-treated 
group. Images are representative for 3 separate experiments. 
 
The inflammatory cell infiltrate in ACD is known to be rich in mononuclear cells including, neutrophils 
(Zollner et al. 2004) and in some models eosinophils have also been reported to infiltrate the inflamed 
skin (Kondo et al. 1998). Both CD4+ and CD8+ T lymphocytes play a major role in the development of 
contact hypersensitivity and cannot be distinguished by H&E staining. CD4+ Th2 cells, in particular, 
are of great interest in this model. They express high levels of GATA3 and are targeted by hgd40 
(Turowska unpublished data). Therefore, it was important to quantify CD4+ T cells in the inflamed skin 
and examine their contribution to the pool of cells infiltrating the skin as well as the effects of hgd40 
treatment on their recruitment to the inflamed skin.  
Immunohistochemical staining for CD4 was performed on PFA-fixed skin sections using 
polyclonal rabbit anti-CD4 and a DAB detection system as described in (2.7.2). 
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Quantification of CD4 cells was achieved by counting positively-stained cells in the 
dermis and basal layer of the epidermis. 
Data indicated only a slight increase in the number of CD4+ T cells infiltrating the dermis 
after oxazolone challenge (Fig. 14A). Treatment with 0.4% hgd40 reduced the number 
of infiltrating CD4+ T cells by about 25%. Furthermore, groups treated with a higher 
concentration of hgd40 showed a more significant decrease with a 30% reduction 
compared to placebo. Treatment with the control DNAzyme (ODNg3) had almost no 
effect on the numbers of CD4 cells infiltrating the skin. As expected, dexamethasone 
treatment had a prominent effect and reduced the numbers by about 48% compared to 
placebo (Fig. 14B). 
3.2.1.3 Effects of DNAzyme treatment on the number of GATA3 expressing cells 
in the dermis 
CD4+ T helper cells are not the only cells expressing GATA3 in the skin. Other cells 
involved in the allergic inflammatory response including, basophils, eosinophils and 
keratinocytes also express GATA3 and can be affected by hgd40 treatment.  
To examine how GATA3 protein expression in the skin was affected, 
immunohistochemical staining was performed as previously described (2.7.2).   
Epidermal keratinocytes express GATA3 and are the first to come in contact with 
topically applied therapeutic reagents. The expression of GATA3 in keratinocytes was 
not altered in inflamed skin compared to normal solvent–challenged skin. It also 
remained stable after treatment with any of the specific or control DNAzymes as well as 
dexamethasone (Fig. 15A).  
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Figure 14. Prophylactic treatment with hgd40 reduced the number of CD4+ cells to baseline 
level. 
(A) Skin sections were stained for CD4 after antigen retrieval and detected using a DAB detection 
system (2.7.2). Images are taken at a 100x magnification and are representative for 2 
independent experiments. (B) Graphical representation of CD4 immunohistochemical staining 
averaged from 3 fields per mouse and 8 mice per group. Data are cumulative from 2 independent 
experiments are shown as mean ± SEM. Significant differences are marked *p ≤ 0.05 and **p ≤ 
0.01 compared to placebo. The numbers above the bars represent the percent of reduction in the 
number of CD4+ cells compared to the placebo group. 
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Figure 15. GATA3 protein expression in epidermal keratinocytes and dermal immune cells 
was not affected after prophylactic treatment with hgd40.  
(A) GATA3 immunohistochemical staining was performed as described in (2.7.2) and sections 
were examined at a 100x magnification. (B) Graphical representation of GATA3
+ 
cells infiltrating 
the dermis averaged from stained cells
 
counted in 3 fields of sight per mouse. Data are compiled 
from 2 separate experiments each with 8 mice per group and are shown as mean ± SEM. 
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3.2.1.4  Effects of DNAzyme treatment on the allergic phenotype  
We showed earlier that skin injury and oxazolone challenge induced an increase in the 
mRNA expression of the Th2 transcription factor GATA3 and its main cytokine IL-4 in 
the inflamed skin (Fig. 11). To investigate the effects of different treatments and 
particularly GATA3-specific DNAzyme on this phenotype, RNA was isolated form skin 
samples as described in (2.6.1) and RT-PCR for the main Th1 and Th2 transcription 
factors and cytokines was performed (2.6.5).  
There was no detectable increase in the levels of GATA3 mRNA expression three days 
after oxazolone challenge. The expression was similar in both oxazolone- and solvent-
challenged groups. It also remained at the same levels in all different treatment groups, 
including both GATA3-specifc DNAzymes. However, the expression of IL-4 was 
significantly induced in response to oxazolone challenge. This increase in the IL-4 mRNA 
expression was significantly impaired after dexamethasone treatment, while groups 
treated with either the control DNAzyme or any of the different doses of hgd40 showed 
no reduction in the levels of IL-4 mRNA.  
There was a tendency of increased Tbet expression in the oxazolone-challenged skin 
upon treatment with the w/o/w emulsion irrespective of the DNAzyme. In the 
dexamethasone group, however, Tbet expression was downregulated to levels lower 
than those in the solvent group. Still, all of these changes did not reach statistical 
significance. 
Similarly, the mRNA expression of the main Th1 cytokine, IFNγ, was elevated at this time 
point following oxazolone challenge. It remained at comparable levels in all treatment 
groups, except for the dexamethasone group where IFNγ expression was significantly 
downregulated (Fig. 16). 
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Figure 16. No changes in the levels of GATA3 and IL-4 mRNA expression after prophylactic 
treatment with hgd40. 
RNA was isolated from skin samples collected on day 3 after challenge. mRNA expression was 
quantified using RT-PCR (2.6.5) after normalization to the house keeping gene L32 and a 
reference sample. Data are compiled from 3 independent experiments (n=6-8 per 
group/experiment) and are shown as mean ± SEM. Significant differences are marked *p ≤ 0.05, 
**p ≤ 0.01 (compared to placebo). 
 
 
GATA3 mRNA is directly targeted by hgd40, and a reduction in its expression is expected 
in such a specific therapy. Improvement of skin swelling was observed on days 2 and 3 
after challenge, yet no reduction in GATA3 mRNA or protein expression was identified 
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in samples collected three days after challenge. GATA3 is expressed normally in the skin 
and its levels are usually elevated during the inflammatory process. In these experiments 
treatment started prior to contact with oxazolone meaning before the induction of an 
inflammatory response. Since the skin was exposed to GATA3-DNAzyme both before 
and after challenge, we wanted to investigate if GATA3 was downregulated at time points 
earlier to those in which the effect on skin swelling was observed. For this reason, mice 
were sensitized and challenged as described before (see Fig. 8A) and similarly treated 
in a prophylactic manner with either placebo or GATA3-specific DNAzyme. Skin samples 
were collected at different time points ( 6 h and 24 h after sensitization and 24 h, 48 h, 
72 h after challenge) and the expression of GATA3-mRNA was quantified with RT-PCR.  
Analysis of all sampling time points revealed that differences in the GATA3 mRNA 
expression were only measurable 6 hours after sensitization. At this time point, GATA3 
expression was significantly downregulated in the group receiving hgd40 treatment 
compared to placebo (Fig. 17).  
 
Figure 17. hgd40 reduced GATA3 mRNA expression in the skin early in the sensitization 
phase. 
Mice were sensitized with oxazolone after prophylactic treatment with hgd40 or placebo and skin 
samples were collected 6 hours after sensitization. mRNA expression was quantified with RT-
PCR after normalization to L32 and a reference sample. Data are compiled from 2 separate 
experiments and are shown as mean ± SEM. Significant differences are marked * p ≤ 0.05. 
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3.2.2 Effects of semi-therapeutic treatment with GATA3-specific DNAzyme 
on oxazolone-induced dermatitis   
Semi-therapeutic treatment refers to a type of treatment in which the first topical 
treatment was performed prior to challenge leaving the sensitization phase unaffected.   
BALB/c mice were sensitized by epicutaneous application of oxazolone to the shaved 
back and challenged three days later with oxazolone at the same site.  A control group 
was sensitized and challenged with solvent only. The first treatment took place 24 h 
before oxazolone challenge and was continued by single daily applications (Fig. 8B).  
Mice were treated by topical application of 50 µl of one of the w/o/w emulsion containing 
either 0.4% or 2% hgd40 (GATA3- specific DNAzyme), 0.4% or 2% ODNg3 (control 
DNAzyme), dexamethasone or no active ingredient (placebo). A detailed description of 
the different groups included in the experiments can be found in table 2 section (2.3.2).  
 
3.2.2.1  Effects of DNAzyme treatment on skin swelling 
As mentioned earlier, inflamed skin becomes swollen and skin thickness measurement 
is used to determine disease progression. There was an acute increase of skin thickness 
in the first 24 h following oxazolone challenge. This increase in skin thickness remained 
on days 2 and 3 in the placebo group and to a comparable extent in the ODNg3 groups 
independent of the dose. The skin was less swollen in the group treated with 0.4% hgd40 
after oxazolone challenge and was significantly reduced on day 3 compared to placebo 
but not to 0.4% ODNg3.  
In the 2% hgd40 treated group, there was a reduction in skin thickness on days 2 and 3 
following the acute increase observed on day 1. This decrease was significant compared 
to both placebo and the 2% ODNg3. Dexamethasone, on the other hand, not only 
prohibited oxazolone-induced skin swelling but also caused thinning of the skin with 
measurements showing values lower than those in the solvent-challenged group (Fig. 
18).  
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Figure 18. hgd40 reduced skin thickness in a dose dependent manner after semi-
therapeutic treatment. 
Mice were sensitized and challenged with oxazolone and treated once daily starting on day -1 
with different emulsions (2.3.2). Skin thickness was measured on days 0, 1, 2, and 3 and deviation 
to day 0 was calculated. Data are compiled from 2 separate experiments each with 8 mice per 
group. Significant differences are marked *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 (compared to 
placebo), ##p ≤ 0.01 and ###p ≤ 0.001(compared to ODNg3).  
 
 
3.2.2.2  Effects of DNAzyme treatment on cellular infiltration 
Examination of skin sections stained with H&E revealed the characteristic dermal 
infiltrate upon oxazolone challenge. This infiltrate has been described in the literature to 
consist of monocytes, neutrophils and eosinophils (Zhang, Tinkle 2000, Kondo et al. 
1998). The density of the cellular infiltrate was comparable in all oxazolone-challenged 
groups with no visible treatment-caused suppression of cellular influx in any of the 
DNAzyme-treated groups. In the group treated with dexamethasone this influx was 
slightly reduced (Fig. 19).  
Quantification of CD4+ cells in the skin after oxazolone challenge and semi-therapeutic 
treatment using immunohistochemical staining showed no differences between the 
different treatment groups (data not shown). 
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Similarly, immunohistochemical analysis of GATA3 in the skin sections was similar to 
that observed in the prophylactic treatment with no significant differences in the numbers 
of GATA3+ cells infiltrating the dermis (data not shown). 
 
 
 
Figure 19. hgd40 treatment did not alter the density of cellular infiltrate in the dermis. 
Skin sample were collected on day 3 and skin sections were stained with H&E and examined at 
100x magnification.  
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3.2.2.3  Effects of DNAzyme treatment on mRNA expression  
The changes in the mRNA expression of the Th2 phenotype profile was analysed using 
quantitative RT-PCR. Similarly, to the findings after prophylactic treatment, there was no 
detectable induction of GATA3 expression in the skin 72 h   after challenge with 
oxazolone and subsequentially no changes in these levels after hgd40 treatment. Yet, in 
the dexamethasone-treated group, the levels of GATA3 expression were significantly 
lower than those measured in the solvent group. 
IL-4 expression, although significantly upregulated after oxazolone challenge, was also 
reduced after dexamethasone treatment but not by any of the hgd40 treatments.  
Moreover, the expression of both Tbet and IFNγ was elevated after oxazolone challenge. 
This was evident in all groups including the negative controls (placebo and ODNg3). In 
the dexamethasone group, the levels of Tbet and IFNγ were only slightly reduced 
compared to placebo (Fig. 20).  
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Figure 20. Semi-therapeutic treatment with hgd40 did not affect the mRNA expression of 
the main Th- associated transcription factors and cytokines. 
mRNA expression was quantified using RT-PCR normalized to the house keeping gene L32 and 
a reference sample. Data are compiled from 2 separate experiments, each with 8 mice per group, 
and are shown as mean ± SEM. Significant differences are marked *p ≤ 0.05. 
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3.3 Effects of Tbet-specific DNAzyme (td32) in an animal model of 
OVA/CFA-induced dermatitis 
The goal of this part of the project was to investigate the effects of a Tbet-specific 
DNAzyme treatment on the progression of a Th1-driven skin inflammation.  
Previously established murine models of skin inflammations combined OVA and the 
adjuvant complete Freund’s adjuvant (CFA) for sensitization to skew a Th1 immune 
response after challenge with OVA (Cho et al. 2001). This published model was used as 
a base for this study with some additional alterations in the mouse strain as well as the 
challenge process.  
In this study and as described in (2.2.2), OVA-TCR transgenic mice (DO11.10) were 
subcutaneously sensitized with OVA emulsified with CFA and one week later challenged 
on three consecutive days by epicutaneous application of OVA to the shaved back skin 
(Fig. 7B). 90% of the CD4+ cells in the DO11.10 mice carry the OVA-specific T cell 
receptor and rapidly react to OVA upon challenge. The Complete Freund’s adjuvant 
drives the CD4 inflammatory response towards a Th1 phenotype thus providing a 
suitable model for targeting Tbet, the major transcription factor of Th1 driven immune 
responses. 
Tbet-specific DNAzyme, named td32, have been established and was formulated in a 
w/o/w emulsion that provides protection and delivery of these molecules after topical 
application. In the following experiments, the effects of preventive treatment with Tbet-
specific DNAzyme was assessed in comparison to either placebo, a control DNAzyme 
(ODNg3) with non-specific binding arms or a GATA3-specific DNAzyme. 
Skin inflammation was elicited as described earlier and mice were treated by topical 
application of 50 µl of either one of the different emulsions twice a day, starting one day 
before challenge (2.3.3). The emulsions were topically applied to the back skin with 12h 
intervals, and gently massaged to help release the active ingredient from the inner 
phase. Table 3 in section (2.3.3) highlights the different treatment groups included in the 
experiments discussed below.  
Skin inflammation was assessed in vivo by daily measurements of skin thickness while 
samples for ex vivo analysis were collected from euthanized mice 4 days after the first 
OVA challenge.   
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3.3.1 Effects of Tbet-specific DNAzyme treatment on skin swelling  
During each experiment, the swelling resulting from the inflammatory reaction was 
monitored by daily measurements of skin thickness. Cumulative data of several 
experiments showed an acute increase in skin thickness in the two days after the first 
OVA-challenge that pesisted until termination day. Compared to placebo, treatment with 
the murine Tbet-specific DNAzyme td32 seemed to slightly decrease the acute reaction 
within the first 24 h. It also continuously and significantly reduced skin swelling by days 
3 and 4 (Fig. 21A). 
To investigate whether these results were due to specific targeting of Tbet or were 
induced by unspecific immune alterations caused by application of synthetic 
deoxyoligonucleotides, the effect detected in the Tbet DNAzyme group was compared 
to that of the control DNAzyme (ODNg3). As expected, the reduction in skin thickness 
was only observed after treatment with Tbet DNAzyme and not with the control 
DNAzyme ODNg3. The differences between these two groups were significant 
throughout the experiment following OVA-challenge (Fig. 21B). 
The immune response in the OVA/CFA model is highly skewed towards Th1 with an 
expected minimum contribution of Th2 cells. To verify the specificity of both the model 
as a Th1-dominant and the Tbet DNAzyme treatment, another group treated with hgd40 
was analysed in parallel to the placebo and td32-treated groups in one of the 
experiments. Again, OVA challenge induced a strong immune reaction that was reflected 
by the acute increase of skin thickness, while no improvement was noted after hgd40 or 
placebo treatment, Tbet DNAzyme treatment, on the other hand, significantly reduced 
skin thickness 4 days after the first challenge with OVA (Fig. 21C).  
In the previous experiments, a dexamethasone treated group was also included. 
However, it was used in the commercially available formula, not the w/o/w formula, which 
was not tolerated and caused a damage to the skin of mice. For this reason, this group 
was excluded from all analyses.  
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Figure 21. td32 treatment reduced OVA-induced skin swelling.  
OVA-TCR tg mice were sensitized with OVA/CFA (s.c.) and seven days later challenged on the 
back skin with OVA on three consecutive days (2.2.2). Treatment started 12 h before challenge 
and continued twice daily until day 3 (2.3.3). Skin thickness was measured on a daily basis and 
differences to day 0 were calculated. Data shown are either combined from 2 independent 
experiments (A) or represent single experiments with n=6 (B and C). Significant differences are 
marked, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 (compared to placebo), and #p ≤ 0.05, ###p ≤ 
0.001(compared to ODNg3).  
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3.3.2 Effects of the Tbet DNAzyme on inflammatory cell influx  
The site of inflammation was optically characterized by the formation of psoriatic plaques. 
Moreover, examination of skin sections stained with H&E revealed all features of a strong 
inflammatory response characterized by substantial epidermal hyperproliferation, edema 
formation and a dense infiltration of immune cells into the site of challenge (Fig. 22).  
The density of cells infiltrating the dermis was comparable between the different 
treatment groups. Moreover, no prominent reduction in the epidermal or dermal 
hyperproliferation was noted in the Tbet-DNAzyme–treated group compared to any of 
the other controls.  
 
 
Figure 22. The density of infiltrating cells in response to OVA challenge remained 
unaffected by DNAzyme treatment. 
OVA-TCR tg mice were sensitized with OVA/CFA (s.c.) and seven days later challenged on the 
back skin with OVA on three consecutive days (2.2.2). Treatment started 12 h before challenge 
and continued twice daily until day 3 (2.3.3). Skin samples were collected on day 4 and sections 
were analysed after H&E staining at a 100x magnification. 
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3.3.3  Effects of preventive treatment on Tbet and IFNγ mRNA expression  
Unlike GATA3, Tbet is not expressed by structural cells but mainly in innate and adaptive 
immune cells including DCs, ILC1 (including NK cells) as well as in CD8+ and Th1 CD4+ 
cells. All of these cells, particularly Th1 and cytotoxic CD8 cells, contribute to the 
inflammatory response in OVA/CFA-induced dermatitis and might be targeted by Tbet-
specific DNAzyme treatment. In addition, Tbet is a major regulator of IFNγ production 
and any interference with Tbet may affect the level of IFNγ as well. To investigate the 
changes in both Tbet and IFNγ expression in the skin, RNA was isolated from skin 
samples of the different treatment groups, reverse transcribed (2.6.4) and analysed by 
RT-PCR as described in (2.6.5). The levels of Tbet mRNA were comparable in the 
groups treated with placebo, the control DNAzyme ODNg3 and Tbet-DNAzyme with no 
significant differences detectable. IFNγ expression, on the other hand was lower in both 
DNAzyme groups compared to placebo with a more prominent reduction in the td32-
treated group (Fig. 23)  
 
Figure 23. Effects of preventive treatment with Tbet-specific DNAzyme on Th1-related 
genes. 
OVA-TCR tg mice were sensitized with OVA/CFA and challenged with OVA as described in 
(2.2.2). Emulsions were applied to the skin twice daily starting on day -1 (2.3.3). RNA was isolated 
from skin samples collected on day 4 and mRNA expression was quantified using RT-PCR and 
normalized to the house keeping gene L32 and a reference sample as described in (2.6.5). Data 
are shown as mean ± SEM with n= 6 and significant differences are marked *p ≤ 0.05, **p ≤ 0.01 
compared to placebo. 
Similar tendencies were observed when the GATA3-specific DNAzyme was used as 
control instead of ODNg3. Preventive treatment with any of the emulsions had no effect 
on the mRNA expression of Tbet and only a very little effect on the Th1 cytokine IFNγ 
(Fig. 24) 
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Figure 24. Effects of preventive treatment with a Tbet-specific DNAzyme (td32) and a 
GATA3-specific DNAzyme (hgd40) on Th1-related genes. 
OVA-TCR tg mice were sensitized with OVA/CFA and challenged with OVA as described in 
(2.2.2). Emulsions were applied to the skin twice daily starting on day -1 (2.3.3). RNA was isolated 
from skin samples collected on day 4 and mRNA expression was quantified using RT-PCR and 
normalized to the house keeping gene L32 and reference sample (2.6.5). Data are shown as 
mean ± SEM with n= 6. 
 
Although Tbet DNAzyme-treatment significantly and specifically reduced skin swelling 
compared to placebo and control DNAzymes, Tbet expression was not affected when 
measured at 96h after the first challenge. The slight reduction in IFNγ expression after 
DNAzyme treatment (both Tbet and the control DNAzyme ODNg3) can be neglected 
since the differences in the ΔCt values were minimal (0.5-1.5 cycle) and within the range 
of inner assay variance. This combined with low sample numbers indicates the low 
physiological relevance of the changes detected. Treatment with the GATA3-specific 
DNAzyme had no effect on skin swelling or the expression of Th1-related genes Tbet 
and IFNγ in the OVA/CFA model.
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4 DISCUSSION 
Atopic dermatitis and psoriasis vulgaris are common chronic, progressive inflammatory 
skin diseases that have been described as polar Th2 verses Th1 diseases (Fonacier et 
al. 2010). The transcription factor GATA3 is an essential factor in allergic inflammation 
through regulating the expression of IL-4, IL-5 and Il-13 and subsequently IgE class 
switching and eosinophilia, all features of AD (Fiset et al. 2006). GATA3 expression is 
increased in AD and decreased in psoriasis (Arakawa et al. 2004, Rácz et al. 2011). 
Tbet, on the other hand, controls the Th1 migratory program and IFNγ production and is 
upregulated in psoriatic skin lesions and PBMCs isolated from psoriatic patients (Odell, 
Cook 2013, Zhang et al. 2014). GATA3 and Tbet play a central role in the development 
and maintenance of AD and psoriasis, respectively. For this reason, targeting these two 
transcription factors on mRNA level by specific DNAzymes may provide a new 
therapeutic approach for both diseases. This is particularly important since current 
treatment regimens are mostly dependent on Glucocorticoids, which are associated with 
a wide range of side effects especially in case of long-term use (Schoepe et al. 2006, 
Schäcke et al. 2002).  
The DNAzymes used in this work have been previously tested in vitro and showed no off 
target effects (Dicke et al. 2012) . The efficacy of GATA3-specific DNAzyme (hgd40) was 
intensively studied both in vitro and in animal models of allergic airway inflammation in 
earlier work (Sel et al. 2008, Turowska et al. 2013).  
 In the current study, we were able to (1) develop an animal model of oxazolone-induced 
dermatitis with a predominant Th2 phenotype (2) show an improvement in the clinical 
symptoms of oxazolone-induced dermatitis after prophylactic and semi-therapeutic 
topical treatment with a GATA3-specific DNAzyme (hgd40) (3) develop an animal model 
of OVA-induced dermatitis with a predominant Th1 phenotype (4) show a reduction in 
the clinical manifestations of skin inflammation by topical treatment with a Tbet-specific 
DNAzyme in an animal model of OVA/CFA dermatitis. 
 
4.1  Induction of a predominant Th2 allergic skin inflammation by skin 
injury and oxazolone  
The immune response in AD is characterized by a Th2 cell-dominant inflammatory 
infiltration, increased expression of Th2 cytokines and elevated levels of IgE. Several 
animal models that show certain features of AD have been developed. These include 
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the use of either mutant mice, such as the Nc/Nga that spontaneously develop AD-like 
skin lesions (Aioi et al. 2001), or transgenic mice overexpressing certain cytokines like 
IL-4 or TSLP (Yoo 2005). However, all these artificial systems do not reflect the 
complexity of AD which is the result of different genetic and environmental factors rather 
than a defect in a single gene. 
In a more generalized model, tape stripping and repeated epicutaneous challenge with 
the protein allergen OVA was used to elicit an AD-like skin inflammation (Spergel et al. 
1999). In this published model, skin sensitization was achieved by the placement of OVA 
on a patch, which was then secured to the skin for a week. In other models, multiple 
challenges with haptens like TNCB and oxazolone were used to induce a chronic Th2-
like hypersensitivity reaction in the skin (Matsumoto et al. 2004, Man et al. 2007). Despite 
the importance of these models for the understanding of AD- pathogenesis, they are less 
convenient for evaluating potential topical therapies. For instance, the placement of the 
patch on the skin in the OVA model hinders topical application at this site. Even if the 
patch were to be temporary removed for topical treatment, the prolonged 
sensitization/challenge required for this model raises the risk of an interaction between 
treatment agents and the antigen. It could inhibit or alters antigen penetration into the 
skin creating misleading results. On the other hand, the extremely severe inflammation 
caused by repeated hapten challenge makes any topical treatment more likely to be 
insufficient. 
In this study, we were able to establish an acute animal model for allergic skin 
inflammation with a prominent Th2 phenotype by combining skin injury and a single 
oxazolone challenge.  
Haptens are commonly used in allergic contact dermatitis (or contact hypersensitivity) 
models. Most haptens like TNCB and DNFB induce a Th1 contact hypersensitivity 
response after a single challenge. Yet, there are contradictory data about the phenotype 
induced by a single oxazolone challenge. While some reported a Th1-dominant response 
(Webb et al. 1998), others described a mixed Th1/Th2 phenotype (Thomson et al. 1993). 
More recently, it was shown that CD4+ T cells infiltrating the skin after oxazolone 
challenge express the chemokine receptor CCR4, which is expressed on Th2 cells 
(Kusumoto et al. 2007). 
Our data revealed a significant upregulation in the mRNA expression of the Th2 
transcription factor GATA3 and main Th2 cytokine IL-4 in tape stripped-oxazolone-
challenged skin. Similar observations were reported following the application of picryl 
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chloride (also known as TNCB) to tape stripped skin (Kondo et al. 1998). Recently 
Oyoshi et al. (Oyoshi et al. 2010) showed that mechanical injury drives skin dendritic 
cells to polarize T cells towards Th2 through the upregulation of TSLP expression by 
keratinocytes. This may explain the Th2-dominant response in our oxazolone model, 
where skin injury was inflicted by tape stripping before antigen application. Despite the 
predominant Th2 phenotype, the prominent increase in IFNγ expression, although not 
significant, suggests that Th1 cells and/or other IFNγ-producing cells also contribute to 
the inflammatory response. 
Local cutaneous inflammation was characterized by edema formation, which was 
reflected in a progressive thickening of the skin throughout the experiment, mild 
epidermal hyperplasia and cellular infiltration.  
The cellular infiltrate in CHS has been widely described in the literature. In a single 
oxazolone-challenge model this infiltrate was found to contain mostly mast cells and T 
lymphocytes (Man et al. 2007), while eosinophils have been reported to infiltrate the skin 
after hapten challenge in barrier disrupted skin (Kondo et al. 1998). The irritant effect 
resulting from mechanical injury as well as the chemical irritation by oxazolone in our 
model can drive the accumulation of neutrophils in the dermis, which in turn increases 
the levels of IFNγ in the skin. Neutrophils are recruited to the skin 24 h after skin injury 
and were reported to have a critical role in the Th2-driven allergic inflammation in the 
OVA model of AD (Oyoshi et al. 2012).  
The animal model presented in this study is a mixed contact hypersensitivity reaction 
with a Th2 predominant phenotype and bears many clinical, immunological and 
histological similarities to AD. Its reproducibility and rapidity makes it a useful tool in 
evaluating both the pathogenic mechanisms and potential topical therapies such as the 
GATA3-specific DNAzyme treatment. 
 
4.2  Effects of GATA3-specific DNAzymes on oxazolone-induced 
dermatitis  
Intensive work has been done to study the effects and safety of the GATA3-specific 
DNAzyme (hgd40) in experimental models of allergic airway inflammation (Sel et al. 
2008, Fuhst et al. 2012, Turowska et al. 2013). Findings from those studies suggest a 
promising potential for the GATA3-specific DNAzyme as future therapy. The similarities 
between asthma and AD in terms of immunopathogenesis and phenotype make it 
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interesting to investigate whether these DNAzymes might also be effective in AD-like 
skin conditions and thus may show comparable results in an animal model of oxazolone-
induced dermatitis.  
The data presented in this study show improvement in the clinical outcomes of 
oxazolone-induced skin inflammation following topical treatment with hgd40. The 
preventive approaches used included two different regimens: a “prophylactic” in which 
the treatment was introduced before sensitization and challenge, and a “semi 
therapeutic” where treatment started before challenge and did not interfere with the 
sensitization phase.  
In both preventive setups, hgd40 treatment resulted in a significant reduction of skin 
thickness by days 2 and 3 post challenge but had no or very little effect on skin swelling 
within the first 24 h following challenge. 
During the sensitization phase, oxazolone-specific T cells are generated and some of 
these cells reside in the skin and can rapidly react to a second encounter with oxazolone. 
However, the irritant effect of oxazolone first activates innate immune mechanisms and 
leads to the accumulation of innate immune cells including mast cells, macrophages and 
neutrophils in the skin. These cells along with keratinocytes secrete pro-inflammatory 
cytokines (IL-1α, IL-1β, and TNFα) that attract more cells and change vascular 
permeability to eventually result in the acute skin swelling measured at 24 h post 
challenge. We found that among all treatment groups it was only dexamethasone that 
suppressed this acute innate response at 24 h. This may be expected since almost all of 
the cells present in the skin express the GC receptor and prophylactic treatment with 
dexamethasone would suppress the transcription of pro-inflammatory genes in these 
cells and reduce the inflammatory process. GATA3 is also expressed by keratinocytes 
and some of the innate immune cells (like NK cells and ILC2) but is most prominent in T 
cells which are first recruited to the skin 24 h after challenge. The strong innate immune 
response overpowers the role of GATA3 in the inflammatory process during the first 24 
h post challenge and can explain why the hgd40 treatment did not inhibit the primary 
irritant skin swelling.  
Nevertheless, GATA3-specific DNAzyme treatment was sufficient to reduce skin swelling 
by days 2 and 3 following provocation with oxazolone, an effect that was both specific 
and dose dependent. Based on skin thickness measurements, topical application of 
0.4% and 2% hgd40 improved the skin swelling while no effect was noted after treatment 
with similar concentrations of the control DNAyzme or placebo. Moreover, it was evident 
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that in both preventive treatments the improvement was more prominent when the higher 
dose 2% of the GATA3-specific DNAyzme (hgd40) was used.  
Synthetic deoxyoligonucleotides can stimulate an innate immune response either 
through the activation of TLR9, which recognizes the CpG motifs in ssDNA (Wagner, 
Bauer 2006) or through DNA sensing receptors that recognize free cytosolic DNA 
molecules (Hornung, Latz 2010). This activation of the innate immune system can 
eventually result in a Th1-biased immune response that counter-regulates the 
development of Th2 allergic reactions. Both hgd40 and ODNg3 used in this study are 
single stranded DNA molecules with CpG motifs in the catalytic domain of their sequence 
and it could be argued that they trigger an innate immune stimulation. However, in our 
study the improvement in the manifestation of oxazolone-induced dermatitis was 
achieved after treatment with GATA3-specific DNAzyme but not the control DNAzyme 
(ODNg3). This supports the concept of a target-specific mode of action of the DNAzyme 
by specific-down regulation of the target molecule, in this case GATA3, in the inflamed 
skin. Even more, potential TLR9-dependent and -independent cell activation by 
DNAzymes were investigated by Dicke et al. using different cell lines and primary cells 
of the innate immune system (Dicke et al. 2012). The findings of this study revealed no 
innate immune-related off target effects of hgd40.  
Despite the effect of both preventive treatments with hgd40 on skin swelling on day 3, 
we did not detect a reduction in the level of GATA3 mRNA expression at this time point.  
In normal, intact skin GATA3 is expressed by structural cells of the epidermis and in the 
hair follicles (Guzman Strong et al. 2006, Kaufman et al. 2003) in addition to some of the 
skin resident immune cells. Our initial findings revealed that 72 h after challenge with 
oxazolone, GATA3 expression was upregulated. However, when combined with 
treatment with any of the emulsions, we did not detect any changes in the GATA3 
expression 72 h following oxazolone challenge. One possible explanation is that the 
application of emulsion somehow affected the sensitization or provocation process. 
Oxazolone is a chemical sensitizer with electrophilic properties. Once it penetrates the 
skin, it can react with skin proteins and form an immunogenic complex. Several factors 
can influence the reaction between an electrophile and an amino acid side chain 
including the 3D structure of the protein and the amino acids’ degree of ionization, which 
in turn is influenced by the pH of the microenvironment (Divkovic et al. 2005). Since we 
apply the emulsion shortly before sensitization and/or challenge, the ingredients of the 
emulsion that penetrated the skin might interact with the hapten and modulate its binding 
to skin proteins resulting in an altered immune response. In our model, we see a 
4. DISCUSSION 
69 
 
tendency towards an increased expression of Tbet after oxazolone challenge only when 
combined with treatment which suggests a change in the immune response and an 
increased participation of the Th1 phenotype. 
If the Th2 phenotype is weaker, detection of small differences in GATA3 expression in 
the cells contributing to the inflammation, might be more difficult. It might also be 
overpowered by the high GATA3 expression in resident skin cells. The DNAzyme used 
in these experiments was designed to specifically target GATA3 mRNA and inhibit its 
translation to protein and therefore hinder the downstream effects of GATA3 in allergic 
reactions. Theoretically, a DNAzyme binds to its target RNA, cleaves it and then de-
attaches and moves to another RNA molecule. The exact turnover or percent of 
reduction in the mRNA within each cell is not known. Previous data and data obtained 
from clinical studies of GATA3-specific DNAzyme-treatment of asthma shows that a 
reduction of 50-70% of the mRNA is sufficient to improve the clinical outcomes 
(unpublished data, properties of sterna biological). In the skin model in hand, we see an 
effect on the manifestation of disease but no measurable downregulation of GATA3 on 
mRNA levels. If these in vivo effects resulted from a 50% reduction in mRNA this would 
be reflected by a one cycle difference in RT-PCR, which makes it very challenging to 
achieve any significant differences with the group sizes used 
When we stained for GATA3 expressing cells in the skin it became obvious that even in 
the solvent group GATA3 was highly expressed both in the epidermis and dermis. 
Similarly to what we see on mRNA level, the number of cells expressing GATA3 in the 
dermis was also comparable between solvent- and oxazolone-challenged skin. None of 
the treatments seemed to significantly affect the numbers of GATA3+ cells infiltrating the 
dermis. Taking into account the 50-70% reduction by hgd40 treatment it would also be 
very challenging to differentiate the intensity of GATA3 expression between cells since 
those cells would still be producing some levels of GATA3 protein and would still stain 
positive for GATA3. The detection protocol cannot discriminate between high or low 
GATA3 expression. Thus the limitation of the detection methods which only discriminates 
between “expression” and “no expression” might account for the absence of treatment 
effects detected upon analysis of GATA3+ cells in the dermis. 
In addition, even with the dexamethasone treatment no changes of GATA3 levels were 
detected, neither on mRNA level nor on the protein expression in the cells. This is in 
contrast to what is known about glucocorticoids and their effect on inhibiting both RNA 
and protein expression of GATA3 (Liberman et al. 2009). These result support the 
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hypothesis that it might indeed be a matter of method sensitivity that makes GATA3 
changes difficult to assess.  
The glucocorticoid dexamethasone suppresses immune mechanisms by binding to the 
GCR and subsequently negatively or positively regulates pro- or anti-inflammatory 
genes, respectively. This was evident in the effects dexamethasone had not only on skin 
thickness, but also on IL-4 and IFNγ expression.  
IL-4 is a major Th2 cytokine and is crucial for inducing GATA3 expression in a STAT6-
dependent manner. GATA3, in turn, activates the transcription of IL-4 resulting in a 
positive feedback loop. The initial source of IL-4 is not exactly clear but several cells are 
known to produce IL-4 including both memory and naïve CD4+ T cell, and some innate 
immune cells like basophils, mast cells and NKT cells (Godfrey, Kronenberg 2004). In 
the oxazolone-challenged groups, IL-4 expression was upregulated but remained 
unaffected by hgd40 treatment while it was significantly downregulated after treatment 
with dexamethasone. We know that GATA3 controls IL-4 gene expression in T cells 
(mainly Th2 cells) and other cells, however, it has been proposed that different 
mechanisms may be involved in IL-4 production in different cells especially those that do 
not express GATA3 such as mast cells (Weiss, Brown 2001). Moreover, it was obvious 
that the cellular infiltration was considerably less in the dexamethasone group, which 
would also be reflected on the mRNA expression levels of different factors including IL-
4 and IFNγ that are usually expressed by different cells infiltrating the skin.  
 
Following oxazolone challenge different immune cells are recruited to the site of 
inflammation. Several studies have shown neutrophils to be the predominant cells 
infiltrating the skin 24 h after challenge (Zhang, Tinkle 2000). While CD4+ T cells, 
although increased after 24 h, were reported to reach their peak in the inflamed skin at 
48-72 h. This is consistent with the occurrence of reduction in skin swelling in the hgd40-
treated groups. 
For this reason, we performed immunohistochemical staining of CD4+ cells in the skin 
and evaluated the changes in the numbers of CD4+ cells infiltrating the skin between 
different groups. We observed comparable numbers of CD4+ cells in the skin of both 
oxazolone-and solvent-challenged groups. Although these groups were differentially 
sensitized and challenged, they both received similar disruption of the skin barrier by 
tape stripping. Mechanical injury of the skin activates the innate immune system and 
leads to the release of cytokines and chemokines which in turn increases the skin 
permeability. Moreover, chemokines work together with an array of adhesion molecules 
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to recruit leucocytes to the skin (Homey et al. 2006). Among these cells might be a variety 
of T lymphocytes including committed and naïve T helper cells that may remain present 
for several weeks after recruitment.  Another cell type that contributes to immune 
responses in the skin is the CD4+ NKT cell. These cells express the TSLP-receptor and 
might be activated and recruited to the skin in response to TSLP (He, Geha 2010), which 
is produced in response to barrier disruption. However, whether these CD4+ cells 
detected in the skin in our model are the result of unspecific innate immune activation of 
the epithelium or specific phenotypes of the T helper subsets remains open for future 
investigations. Nevertheless, based on the cytokine profile in the oxazolone-challenged 
groups, the CD4+ T cells in these groups are more likely to be a mix of both Th1 and Th2 
cells.  
Th2 cell, in particular, are of great interest in this model. The differentiation, proliferation 
and cytokine secretion function of Th2 cells is controlled by GATA3 and these cells 
represent direct targets for GATA3-specific DNAzyme treatment.  
We found that in the prophylactic model, the number of CD4+ cells that infiltrated the skin 
of hgd40-treated groups was less than in the control DNAzyme or placebo groups. This 
decrease was also more prominent when a higher dose of hgd40 was used. However, 
we did not find a similar effect on CD4+ cells when animals were treated with either of 
the two doses of hgd40 in a semi-therapeutic manner. These results suggest that 
interfering with GATA3 in the sensitization phase modulates the inflammatory process 
and later affects the infiltration of CD4+ cells into the skin. This might be an effect on the 
hapten and its binding to skin protein or an effect on early immune events and cytokines 
in the microenvironment that would later influence the participation of certain cells.  
Based on these findings we investigated the changes in GATA3 expression in the 
prophylactic treatment model at earlier time points both after sensitization and challenge. 
Consistent with what we speculated, it was early after sensitization - at only 6h - that a 
down-regulation of GATA3 mRNA level was detected in the hgd40-treated group but not 
in the placebo group. At this early time point, generation of oxazolone-specific T cells is 
not to be expected. Yet, other cells expressing GATA3 such as skin resident T cells and 
innate immune cells that are recruited to the skin could be the ones affected. Recently, 
innate lymphoid cells (ILCs) have been identified as a group of cells bearing the 
phenotypical features of lymphoid cells without carrying the antigen specific receptor of 
adaptive immune cells. Group 2 of the ILCs produce Th2 cytokines including IL-5 and IL-
13 and their differentiation and function is mainly controlled by GATA3 (Hoyler et al. 
2012, Mjösberg et al. 2012). These cells reside in healthy human and murine skin and 
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are enriched in AD skin lesions (Kim et al. 2013). In this work of Kim et al. the researchers 
found group 2 ILCs (ILC2) to be crucial for the development of skin inflammation in 
murine models of AD. These group2 ILC responses in the skin were highly depended on 
TSLP-TSLPR interaction. We know from the previous work of Oyoshi et al. (Oyoshi et 
al. 2010) that tape stripping results in elevated levels of TSLP in the skin. Therefore, it is 
very likely that the early downregulation of GATA3 mRNA in our model is the result of 
.targeting GATA3 in these particular early-responsive group 2 ILCs. 
The exact mechanism by which ILC2 promote AD-inflammation is not yet known but ILC2 
derived IL-5 and IL-13 may be directly or indirectly responsible for a series of events 
leading to the inflammatory response in AD. As mentioned earlier, GATA3 is important 
for the function of ILC2 and their cytokine production. If the expression of GATA3 in these 
cells was affected by GATA3-specific DNAzyme treatment, this would change the 
cytokine milieu and affect other innate and later adaptive immune reactions and result in 
a modulation of the inflammation which might account for the reduction of skin swelling.  
However, at this stage more studies are still needed to understand the mechanisms by 
which ILCs contribute to both innate and adaptive immunity.  
Our results clearly show a treatment effect on the manifestation of oxazolone-induced 
dermatitis after GATA3-specific DNAzyme treatment in both preventive approaches. This 
effect was reflected by a significant and dose-dependent reduction in skin swelling in the 
GATA3-specific- but not the control-DNAzyme-treated group. However, a down-
regulation of the targeted mRNA was only detectable early in the sensitization phase 
after the prophylactic treatment.  We believe that once the inflammatory process starts 
with different cells recruited to the skin and high levels of cytokines being produced, 
including IL-4 which up-regulates GATA3 expression, changes in the levels of GATA3 
become more difficult to detect. In addition, this early down-regulation of GATA3 may 
have created an altered cytokine- and maybe even chemokine milieu. This in turn would 
have affected different aspects of the inflammatory process including the infiltration of 
CD4 cells. These changes may also involve alterations in the expression pattern of 
adhesion molecules, vascular permeability and edema formation or other mechanisms 
involved in the clearance of inflammation. However, analysis of whether or not GATA3 
or one of its downstream targets can influence any of these events is beyond the scope 
of this project and open for future studies. 
Based on the findings of this study, we believe that hgd40 may represent a promising 
therapeutic agent for topical application in Th2-driven inflammatory skin diseases.  
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4.3  Effects of Tbet-specific DNAzyme treatment in vivo  
Tbet, the major regulator of differentiation and function of Th1 cells, represents an 
important therapeutic target in autoimmune and Th1-driven diseases. Therefore, a 
specific DNAzyme targeting Tbet mRNA was designed and formulated in a W/O/W 
emulsion suitable for topical application in vivo.  
The aim of this part of the project was to analyse the ability of this DNAzyme to interfere 
with disease progression when applied in Th1-predominant skin inflammation. We chose 
an animal model of OVA/CFA-induced dermatitis to test the effects of Tbet-specific 
DNAzyme in vivo. The combination of CFA as an adjuvant with the protein antigen OVA 
for sensitization has been described to allow a preferential differentiation towards Th1 
immune responses (Shibaki, Katz 2002). This could be due to the mycobacterial 
products in the CFA, which create a cytokine milieu more suitable for Th1 cell 
differentiation. Similar murine models have been used to study a Th1-/IFNγ- induced skin 
inflammation (Cho et al. 2001). 
In this model we see a strong inflammation in response to repeated cutaneous OVA 
challenge characterized by a significant increase in skin swelling and formation of 
psoriatic plaques. The inflammatory reaction in the skin was also characterized by a 
dense influx of inflammatory cells consisting mostly of mononuclear cells and 
neutrophils. Following semi-therapeutic topical treatment with the Tbet-specific 
DNAzyme td32, a significant reduction in skin swelling was evident. No reduction was 
detected when skin was treated with either ODNg3 or placebo which suggests specific 
targeting of Tbet by td32. Moreover, our findings also revealed no effects of topical 
treatment with hgd40 on skin swelling in the OVA/CFA model, which further supports the 
previously mentioned reports of the favoured Th1 phenotype in such models. It also 
emphasizes our hypothesis that the improvement in skin swelling is the result of specific 
targeting of Tbet. 
Unlike what was detected for the GATA3-DNAzyme treatment in the oxazolone model, 
preventive treatment with the Tbet-DNAzyme reduced the severity of disease 
progression including the acute phase following first challenge. This may be due to the 
fact that many of the immune cells involved in the first response (including NK cells, ILC1, 
γδ T cells) express Tbet (Lazarevic et al. 2013) and thus might be affected by Tbet-
DNAzyme treatment. At a later phase of disease progression, we believe that adaptive 
immune cells including both CD4+ Th1cells and CD8+ CTLs become the predominant 
cells and can be directly affected by Tbet-DNAzyme treatment. 
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However, and despite the significant effect on skin swelling, we were unable to detect a 
down-regulation in the mRNA of Tbet at the endpoint in these experiments. These results 
are consistent with our findings in the oxazolone model after treatment with the GATA3-
DNAzyme. It is possible that the changes on mRNA level of Tbet appear at an earlier 
time point as it is the case in the oxazolone model. Even more, the effects of such an 
early change in Tbet and perhaps cytokine environment may have led to a series of 
events that eventually resulted in the improvement of clinical manifestation of skin 
inflammation we observed after treatment.  
There was a slight, yet significant, reduction in IFNγ expression in the Tbet-specific 
DNAzyme- which unexpectedly was also detected for the control DNAzyme ODNg3-
treated group but to a lesser extent. While these effects on IFNγ seem to correlate with 
those on skin swelling in the Tbet DNAzyme group, they are inconclusive for the ODNg3 
group especially as they were not associated with any improvement in this group. 
Unspecific effects of deoxyoligonucletides would involve an induction of IFNγ rather than 
a suppression. Moreover, previous studies showed no off-target effects of ODNg (Dicke 
et al. 2012). The ODNg3 DNAzyme possesses the active catalytic domain with unspecific 
binding arms of scrambled sequence. They showed no effect on IFNγ in the oxazolone 
model or on the symptomatic outcome of either model. Therefore it is also very unlikely 
that this effect is a result of these DNAzyme binding to IFNγ-mRNA or the mRNA of IFNγ-
regulating molecules. The effect on IFNγ expression is most likely an artificial effect 
especially since the actual differences in the raw data of the qPCR regarding the delta 
Ct values are minimal within the range of inner assay variance. This combined with low 
sample numbers points to the low physiological relevance of the changes detected. 
 In this part of the study we were able to show efficacy of Tbet-specific DNAzyme 
treatment on OVA-induced dermatitis in vivo but no down-regulation of Tbet 96h after 
the last challenge. The similarities of these findings with those of the GATA3-DNAzyme 
in the oxazolone model point to possibly similar modes of action in each of the models. 
Yet, many aspects of the exact chain of events leading to these final results remain 
unclear and might be a matter for future investigations. 
 
4.4  Pros and Cons of DNAzyme-based therapy   
During the past decade, our understanding of disease pathogenesis has improved 
remarkably. The explosion in the genomic information has led to discoveries of disease-
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causing proteins and pathways and opened the door for new, gene-specific therapies 
such as DNAzymes.  
The use of DNAzymes as therapeutic tools in different diseases including cancer and 
allergic diseases have grown in recent years and in some cases progressed to clinical 
trials (Khachigian 2004, Badros et al. 2005, Cai et al. 2012 and Krug et al. 2015). 
Generally, several criteria can determine the success of DNAzyme therapy including the 
choice of the target gene and the ability of the DNAzyme to cleave its target mRNA.  
In this study, the targeted molecules GATA3 and Tbet, are main orchestrators of the T 
helper cell mediated immune responses in each of the respective models. In addition 
both hgd40 and td32 have been shown to cleave their targets in previous in vitro studies 
(Sel et al. 2008 and unpublished data). 
Nevertheless, in vivo application of DNAzymes bares other challenges starting with 
protection of the DNAzymes from degradation and a successful delivery to the site of 
action. This issue was addressed through a combination of chemical alterations to the 
DNAzyme structure and a drug delivery system that provided both protection and 
enhanced skin penetration (Schmidts et al. 2012). Although the distribution of DNAzymes 
after topical application to the skin was beyond the scope of this study, the effective 
reduction in skin swelling seen exclusively in the specific DNAzyme, and not the control 
DNAzyme, suggests a successful delivery. Similar effective treatment has been reported 
for the intranasaly applied GATA3-specific DNAzyme in murine models of allergic airway 
inflammation (Sel et al. 2008). Later, biodistribution studies involving inhalative exposure 
of the GATA3-specific DNAzyme hgd40 showed efficient delivery of fluorescently 
labelled hgd40 into the lung tissues (Turowska et al. 2013). Comparable studies in the 
skin are planned, but are expected to be challenging due to the high autofluorescence 
of the skin.  
Although the field of DNAzyme therapy is expanding, the use of DNAzymes in skin or 
airway diseases has the advantage of a topical drug delivery to the target tissue by 
epicutaneous emulsions or inhaled aerosols. Topical application also bares lower risk of 
toxicity compared to systemic administration of such antisense molecules. The 
previously referred to work by Turowska et al. described a rapid availability and 
elimination of hgd40 from the plasma following pulmonary administration. Even more, 
toxicological analysis of these molecules in rats and dogs revealed no hgd40-related 
respiratory, cardiovascular or CNS effects (Turowska et al. 2013). In general, drug 
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application through the cutaneous root is considered safer and the concentrations of the 
drugs reaching the blood after once or twice daily applications are expected to be 
minimal. Moreover, the data provided from previous studies as well as the one at hand 
indicate no off-target effects of theses DNAzymes by activation of innate immune 
responses via TLR9 of DNA-sensing molecules.  
The GATA3-specific DNAzyme hgd40 used in this study has already moved to clinical 
trials (phase I and IIa for asthma bronchiale and atopic dermatitis). Most recent published 
data reported a safe and well tolerability of inhaled GATA3-specific DNAzymes in phase 
I clinical trials (Homburg et al. 2015). Furthermore, data obtained from a randomized, 
double blind clinical trial showed significant reduction in both early and late allergic 
response in asthmatic patients after treatment with GATA3-specific DNAzyme (Krug et 
al. 2015). 
Despite the efficacy and safety profile available so far for this transcription factor-specific 
DNAzyme, there is still a long way for such therapies to reach the bedside. However, the 
results of this study support the previous findings on successful reduction of Th2-driven 
allergic inflammation through the down-regulation of GATA3. It also shows promising 
results for the Tbet-specific DNAzyme in Th1-driven skin inflammation. These findings 
open a new possibility for a novel DNAzyme-based therapy in the treatment of Th-
mediated skin diseases.
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5 SUMMARY 
Inflammatory skin diseases cover a wide range of skin conditions that cause dry, itchy, 
scaly skin and affects millions around the world. Current therapies are mostly 
symptomatic and often associated with a wide range of side effects. Therefore, there is 
a growing need for a more specific therapy targeting key molecules in the pathogenesis 
of such diseases. Investigations revealed a central role for different T helper subsets in 
the immunopathology of these skin diseases. Atopic dermatitis (Th2), contact dermatitis 
(Th1) and Psoriasis (Th1, Th17), are associated with one or more of these Th-
phenotypes. The differentiation and activation of T helper subtypes is regulated by 
different transcription factors. This study focused on two specific transcription factors 
GATA3 and Tbet, which regulate the differentiation and activation of Th2 and Th1, 
respectively. The levels of these transcription factors were found to be elevated in 
diseases with the respective Th phenotype, which made them interesting targets for 
DNAzyme-based therapy. In order to test the efficacy of such transcription factor-specific 
DNAzymes, two different animal models of inflammatory allergic skin diseases were 
established. In the first model skin injury and the hapten oxazolone were used to elicit a 
Th2-dominant contact hypersensitivity with features similar to those of atopic dermatitis. 
In the second model, Ovalbumin was used to induce a Th1-dominated inflammation in 
OVA-specific T cell receptor- transgenic mice after systemic sensitization with OVA/CFA. 
Effects of topical preventive treatment with GATA3-specific DNAzyme (hgd40) were 
investigated in the oxazolone model. The DNAzymes were formulated in w/o/w emulsion 
for protection against degradation and an enhanced skin penetration. Compared to 
placebo and control non-specific DNAzyme ODNg3, prophylactic treatment with hgd40 
significantly reduced skin swelling. It also resulted in lower numbers of CD4+ cells 
infiltrating the dermis. This was associated with a downregulation of GATA3 mRNA 
expression in the skin early in the sensitization phase. Similar reduction in skin swelling 
was also observed after a semi-therapeutic treatment, in which hgd40 was first applied 
24 h prior to challenge but not during sensitization. 
Using the OVA/CFA model, effects of the Tbet-specific DNAzyme td32 treatment were 
evaluated. Data indicated a significant reduction in skin swelling following prophylactic 
treatment with emulsions containing td32. No such effect was observed in the control 
DNAzyme ODNg3 or placebo groups. In addition, no influence on the progression of skin 
swelling in this Th1-skewed skin inflammation after treatment with hgd40 was detected, 
which further supports the hypothesis of specific targeting of Tbet.  
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In summary, this study shows that treatment with DNAzymes, targeting Th1- and Th2- 
specific transcription factors Tbet and GATA3 improved inflammatory symptoms in vivo. 
These results pose the DNAzyme as promising tools for future topical treatment of 
inflammatory skin diseases.  
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6 ZUSAMMENFASSUNG 
Entzündliche Erkrankungen der Haut sind durch trockene, juckende und schuppende 
Veränderungen des betroffenen Organs gekennzeichnet. Derzeitige Therapien 
behandeln meist nur die Symptome und sind häufig mit einem großen Spektrum an 
Nebenwirkungen verbunden. Es gibt daher einen wachsenden Bedarf an spezifischeren 
Therapieoptionen, welche Schlüsselmoleküle in der Immunopathologie dieser 
Krankheiten adressieren. Verschiedene Untergruppen von T-Helferzellen spielen eine 
zentrale Rolle bei der Entwicklung dieser Hauterkrankungen. Die Differenzierung und 
Aktivierung dieser T-Helferzell (TH)-Subtypen wird durch verschiedene 
Transkriptionsfaktoren reguliert. In dieser Arbeit liegt der Fokus auf dem TH2- bzw TH1-
induzierenden Transkriptionsfaktor GATA3 bzw Tbet, Die atopische Dermatitis (TH2) 
sowie die Kontaktdermatitis und Psoriasis (TH1) werden mit einem der beiden TH-Zell-
Phänotypen assoziiert. In den jeweiligen Erkrankungen konnten  erhöhte Mengen des 
entsprechenden Transkriptionsfaktors nachgewiesen werden, was diese Moleküle zu 
einer interessanten Zielstruktur für eine DNAzym- Therapie macht. Um die Effizienz von 
Transkriptionsfaktor-spezifischen DNAzymen zu testen, wurden zwei verschiedene 
Tiermodelle für entzündliche Hauterkrankungen etabliert. Im ersten Modell wurde durch 
mechanische Schädigung der Haut und dem Hapten Oxazolon eine TH2-dominierte 
Kontakthypersensitivität ausgelöst, deren Eigenschaften der Atopischen Dermatitis 
entsprechen. Im zweiten Modell wurde in OVA-T-Zell-Rezeptor-transgenen Mäusen, 
nach OVA/CFA Sensibilisierung und anschließender lokaler OVA-Applikation eine TH1-
dominierte Entzündung ausgelöst.  
Die Effekte einer präventiven lokalen Behandlung mit dem GATA3-spezifischen 
DNAzym hgd40, wurde im Oxazolon-Modell untersucht. Zum Schutz und zur 
Penetrationsförderung des Moleküls, wurde dieses in eine  w/o/w Emulsion eingebracht. 
Im Vergleich zum Placebo und dem unspezifischen DNAzym ODNg3 zeigte die 
prophylaktische Behandlung mit hgd40 eine signifikante Reduktion der Hautschwellung. 
Ebenso konnte eine geringere Anzahl an infiltrierenden CD4+ Zellen in die Dermis 
beobachtet werden. Dieser Beobachtung ging in der frühen Sensibilisierungsphase eine 
niedrigere GATA3 mRNA Expression in der Haut  voraus. Eine ähnliche Abnahme der 
Hautschwellung wurde nach einer semi-therapeutischen Behandlung beobachtet, in der 
hgd40 erst 24 Stunden vor Provokation aber nicht vor der Sensibilisierung appliziert 
wurde. 
Die Effekte der Behandlung mit dem Tbet-spezifischen DNAzym td32 wurden im 
OVA/CFA-Modell evaluiert. Die Daten zeigen eine geringere Hautschwellung nach 
prophylaktischer Behandlung mit einer td32-Emulsion, während keine Effekte nach 
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Behandlung mit dem Kontroll-DNAzym ODNg3 oder dem  Placebo zu beobachten 
waren. Zusätzlich konnte gezeigt werden, dass die Behandlung mit hgd40 keinen 
Einfluss auf die Entwicklung der Hautschwellung in dieser TH1-dominierten Entzündung 
hat. Dies unterstützt die Hypothese der spezifischen Interaktion des DNAzyms mit Tbet. 
Zusammenfassendkonnte gezeigt werden, dass durch die Behandlung mit DNAzymen, 
gerichtet gegen die TH2- und TH1- spezifischen Transkriptionsfaktoren GATA3 und Tbet   
eine Verbesserung der Entzündungssymptome in vivo erreicht werden konnte. Diese 
Ergebnisse zeigen, dass DNAzyme als vielversprechendes Instrument für die zukünftige 
lokale Behandlung entzündlicher Hautkrankheiten darstellen können. 
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A Adenine 
ACD Allergic contact dermatitis  
AD Atopic dermatitis  
AMPs  Antimicrobial peptides  
APCs Antigen- presenting cells  
Bp Base pair 
C Cytosine 
CCL  CC- chemokines ligand  
CCR CC- chemokine receptor  
CD Cluster of differentiation  
cDNA Complementary DNA 
CFA Complete Freund's adjuvant 
CHS Contact hypersensitivity  
CLA Cutaneous lymphocyte- associated antigen 
CpG Cytosine-guanine-dinucleotide motive 
CXCL  CXC- chemokine ligand  
DAMPs  Danger -associated molecular patterns  
DCs  Dendritic cells  
Dexa Dexamethasone 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic Acid 
DNAzymes Deoxyribozymes 
DNFB Dinitrofluorobenzene 
dNTP Deoxynucleoside triphosphate  
Fig.  Figure 
G Guanine 
GATA3  GATA binding protein 3 
Gfi-1 Growth factor independent -1  
GM-CSF Granulocytes macrophages- colony stimulating factor  
GR Glucocorticoid receptors  
H&E Hematoxylin and eosin 
i.p.  intraperitoneal  
IFNγ Interferon gamma  
IFNγR Interferon gamma receptor 
IgE Immunoglobulin type E 
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IHC Immunohistochemistry 
IL- Interleukin- 
IL-12Rβ2 IL-12 receptor beta 2 
ILCs  Innate lymphoid cells  
iNKT  Invariant natural killer T cell  
IκBα Inhibitors of nuclear factor κB 
KCs Keratinocytes 
LCs  Langerhans cells  
LNAs Locked nucleic acids  
MHC  Major histocompatibility complex  
mRNA  messenger RNA  
NFAT nuclear factor of activated T cells  
NKT  Natural killer T cell  
NLAs Locked nucleic acids  
NLRs  NOD-like receptors  
ODN Oligodeoxynucleotide 
OVA Ovalbumin 
Oxa Oxazolone  
PAMPs  Pathogen-associated molecular patterns 
PBMCs Peripheral blood mononuclear cells  
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
RNA Ribonucleic acid  
RT Room temperature 
RT-PCR Real time PCR 
s.c. subcutaneous  
SLPI Secretory leukocyte protease inhibitor  
SNPs  Single nucleotide polymorphisms  
ssDNA Single stranded DNA 
STAT Signal transducer and activator of transcription  
T Thymine 
TAE Tris acetate EDTA 
Tbet T box expressed in T cells  
TCI  Topical calcineurine inhibitors  
TCR T cell receptor  
Th  T helper  
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TLRs  Toll- like receptors  
TNF Tumour necrosis factor  
TNFα Tumour necrosis factor alpha  
Tregs  T regulatory cells  
TSLP Thymic stromal lymphopoietin 
UV Ultra violet  
w/o  Water in oil  
w/o/w Water in oil in water  
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